US008029504B2

(12) **United States Patent**
Long

(10) **Patent No.: US 8,029,504 B2**
(45) **Date of Patent: *Oct. 4, 2011**

(54) **ELECTROPORATION ABLATION APPARATUS, SYSTEM, AND METHOD**

(75) Inventor: **Gary L. Long**, Cincinnati, OH (US)

(73) Assignee: **Ethicon Endo-Surgery, Inc.**, Cincinnati, OH (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/635,298**

(22) Filed: **Dec. 10, 2009**

(65) **Prior Publication Data**

US 2010/0087813 A1 Apr. 8, 2010

Related U.S. Application Data

(63) Continuation of application No. 11/706,766, filed on Feb. 15, 2007, now Pat. No. 7,655,004.

(51) **Int. Cl.**
A61B 18/04 (2006.01)
A61B 1/00 (2006.01)

(52) **U.S. Cl.** **606/37**; 600/103

(58) **Field of Classification Search** 606/32–52; 600/101, 104, 106, 137, 153, 160; 607/96–100
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

645,576	A	3/1900	Telsa
649,621	A	5/1900	Tesla
787,412	A	4/1905	Tesla
1,127,948	A	2/1915	Wappler
1,482,653	A	2/1924	Lilly
1,625,602	A	4/1927	Gould et al.
2,028,635	A	1/1936	Wappler
2,113,246	A	4/1938	Wappler
2,155,365	A	4/1939	Rankin
2,191,858	A	2/1940	Moore
2,196,620	A	4/1940	Attarian
2,388,137	A	10/1945	Graumlich
2,493,108	A	1/1950	Casey, Jr.
2,504,152	A	4/1950	Riker et al.
2,952,206	A	9/1960	Becksted
3,069,195	A	12/1962	Buck
3,170,471	A	2/1965	Schnitzer

(Continued)

FOREIGN PATENT DOCUMENTS

DE 3008120 A1 9/1980

(Continued)

OTHER PUBLICATIONS

Michael S. Kavic, M.D., "Natural Orifice Translumenal Endoscopic Surgery: "NOTES"", JSLS, vol. 10, pp. 133-134 (2006).

(Continued)

Primary Examiner — Michael Peffley
Assistant Examiner — Ronald Hupczey, Jr.

(57) **ABSTRACT**

A surgical instrument, such as an endoscopic or laparoscopic instrument, includes an ablation device. The ablation device includes an elongate member comprising first and second channels. First and second probes are disposed within the respective first and second channels, where the first and second probes each define a central axis. First and second electrodes are coupled to distal ends of the respective first and second probes. A distance between the first and second electrodes is adjustable by rotating at least one of the first and second probes about the central axis of the at least one of the first and second probes.

35 Claims, 12 Drawing Sheets



U.S. PATENT DOCUMENTS

3,435,824 A 4/1969 Gamponia
3,470,876 A 10/1969 Barchilon
3,669,487 A 6/1972 Roberts et al.
3,746,881 A 7/1973 Fitch et al.
3,799,672 A 3/1974 Vurek
3,946,740 A 3/1976 Bassett
3,994,301 A 11/1976 Agris
4,011,872 A 3/1977 Komiya
4,012,812 A 3/1977 Black
4,164,225 A 8/1979 Johnson et al.
4,178,920 A 12/1979 Cawood, Jr. et al.
4,207,873 A 6/1980 Kruy
4,235,238 A 11/1980 Ogiu et al.
4,258,716 A 3/1981 Sutherland
4,278,077 A 7/1981 Mizumoto
4,285,344 A 8/1981 Marshall
4,311,143 A 1/1982 Komiya
4,396,021 A 8/1983 Baumgartner
4,452,246 A 6/1984 Bader et al.
4,461,281 A 7/1984 Carson
4,491,132 A 1/1985 Aikins
4,527,331 A 7/1985 Lasner et al.
4,527,564 A 7/1985 Eguchi et al.
4,538,594 A 9/1985 Boebel et al.
D281,104 S 10/1985 Davison
4,580,551 A 4/1986 Siegmund et al.
4,646,722 A 3/1987 Silverstein et al.
4,653,476 A 3/1987 Bonnet
4,669,470 A 6/1987 Brandfield
4,671,477 A 6/1987 Cullen
4,685,447 A 8/1987 Iversen et al.
4,711,240 A 12/1987 Goldwasser et al.
4,712,545 A 12/1987 Honkanen
4,721,116 A 1/1988 Schintgen et al.
4,733,662 A 3/1988 DeSatnick et al.
D295,894 S 5/1988 Sharkany et al.
4,763,669 A 8/1988 Jaeger
4,770,188 A 9/1988 Chikama
4,823,794 A 4/1989 Pierce
4,829,999 A 5/1989 Auth
4,873,979 A 10/1989 Hanna
4,880,015 A 11/1989 Nierman
4,911,148 A 3/1990 Sosnowski et al.
4,926,860 A 5/1990 Stice et al.
4,938,214 A 7/1990 Specht et al.
4,950,273 A 8/1990 Briggs
4,950,285 A 8/1990 Wilk
4,984,581 A 1/1991 Stice
5,007,917 A 4/1991 Evans
5,010,876 A 4/1991 Henley et al.
5,020,514 A 6/1991 Heckele
5,020,535 A 6/1991 Parker et al.
5,025,778 A 6/1991 Silverstein et al.
5,033,169 A 7/1991 Bindon
5,037,433 A 8/1991 Wilk et al.
5,041,129 A 8/1991 Hayhurst et al.
5,046,513 A 9/1991 Gatturna et al.
5,050,585 A 9/1991 Takahashi
5,065,516 A 11/1991 Dulebohn
5,066,295 A 11/1991 Kozak et al.
5,123,913 A 6/1992 Wilk et al.
5,123,914 A 6/1992 Cope
5,133,727 A 7/1992 Bales et al.
5,174,300 A 12/1992 Bales et al.
5,176,126 A 1/1993 Chikama
5,190,050 A 3/1993 Nitzsche
5,190,555 A 3/1993 Wetter et al.
5,192,284 A 3/1993 Pleatman
5,201,752 A 4/1993 Brown et al.
5,201,908 A 4/1993 Jones
5,203,785 A 4/1993 Slater
5,203,787 A 4/1993 Noblitt et al.
5,209,747 A 5/1993 Knoepfler
5,217,003 A 6/1993 Wilk
5,217,453 A 6/1993 Wilk
5,219,357 A 6/1993 Honkanen et al.
5,219,358 A 6/1993 Bendel et al.
5,222,362 A 6/1993 Maus et al.
5,222,965 A 6/1993 Haughton
5,234,453 A 8/1993 Smith et al.
5,235,964 A 8/1993 Abenaim
5,242,456 A 9/1993 Nash et al.
5,246,424 A 9/1993 Wilk
5,259,366 A 11/1993 Reydel et al.
5,263,958 A 11/1993 deGuillebon et al.
5,273,524 A 12/1993 Fox et al.
5,275,607 A 1/1994 Lo et al.
5,284,128 A 2/1994 Hart
5,284,162 A 2/1994 Wilk
5,287,845 A 2/1994 Faul et al.
5,290,299 A 3/1994 Fain et al.
5,290,302 A 3/1994 Pericic
5,295,977 A 3/1994 Cohen et al.
5,297,536 A 3/1994 Wilk
5,301,061 A 4/1994 Nakada et al.
5,312,351 A 5/1994 Gerrone
5,312,416 A 5/1994 Spaeth et al.
5,312,423 A 5/1994 Rosenbluth et al.
5,320,636 A 6/1994 Slater
5,325,845 A 7/1994 Adair
5,330,471 A 7/1994 Eggers
5,330,486 A 7/1994 Wilk
5,330,488 A 7/1994 Goldrath
5,330,496 A 7/1994 Alferness
5,330,502 A 7/1994 Hassler et al.
5,331,971 A 7/1994 Bales et al.
5,334,198 A 8/1994 Hart et al.
5,344,428 A 9/1994 Griffiths
5,350,391 A 9/1994 Iacovelli
5,352,184 A 10/1994 Goldberg et al.
5,352,222 A 10/1994 Rydell
5,354,302 A 10/1994 Ko
5,354,311 A 10/1994 Kambin et al.
5,356,408 A 10/1994 Rydell
5,364,408 A 11/1994 Gordon
5,364,410 A 11/1994 Failla et al.
5,366,466 A 11/1994 Christian et al.
5,366,467 A 11/1994 Lynch et al.
5,368,605 A 11/1994 Miller, Jr.
5,370,647 A 12/1994 Graber et al.
5,374,273 A 12/1994 Nakao et al.
5,374,275 A 12/1994 Bradley et al.
5,377,695 A 1/1995 An Haack
5,383,877 A 1/1995 Clarke
5,383,888 A 1/1995 Zvenyatsky et al.
5,391,174 A 2/1995 Weston
5,392,789 A 2/1995 Slater et al.
5,395,386 A 3/1995 Slater
5,401,248 A 3/1995 Bencini
5,403,328 A 4/1995 Shallman
5,403,342 A 4/1995 Tovey et al.
5,403,348 A 4/1995 Bonutti
5,405,073 A 4/1995 Porter
5,405,359 A 4/1995 Pierce
5,409,478 A 4/1995 Gerry et al.
5,417,699 A 5/1995 Klein et al.
5,423,821 A 6/1995 Pasque
5,433,721 A 7/1995 Hooven et al.
5,439,471 A 8/1995 Kerr
5,439,478 A 8/1995 Palmer
5,441,059 A 8/1995 Dannan
5,441,499 A 8/1995 Fritzsch
5,449,021 A 9/1995 Chikama
5,456,684 A 10/1995 Schmidt et al.
5,458,131 A 10/1995 Wilk
5,458,583 A 10/1995 McNeely et al.
5,460,168 A 10/1995 Masubuchi et al.
5,460,629 A 10/1995 Shlain et al.
5,462,561 A 10/1995 Voda
5,465,731 A 11/1995 Bell et al.
5,467,763 A 11/1995 McMahon et al.
5,468,250 A 11/1995 Paraschac et al.
5,470,308 A * 11/1995 Edwards et al. 604/22
5,470,320 A 11/1995 Tiefenbrun et al.
5,478,347 A 12/1995 Aranyi
5,480,404 A 1/1996 Kammerer et al.
5,482,054 A 1/1996 Slater et al.

5,484,451 A 1/1996 Akopov et al.
5,489,256 A 2/1996 Adair
5,496,347 A 3/1996 Hashiguchi et al.
5,499,990 A 3/1996 Schülken et al.
5,499,992 A 3/1996 Meade et al.
5,501,692 A 3/1996 Riza
5,503,616 A 4/1996 Jones
5,505,686 A 4/1996 Willis et al.
5,507,755 A 4/1996 Gresl et al.
5,511,564 A 4/1996 Wilk
5,514,157 A 5/1996 Nicholas et al.
5,522,829 A 6/1996 Michalos
5,522,830 A 6/1996 Aranyi
5,527,321 A 6/1996 Hinchliffe
5,540,648 A 7/1996 Yoon
5,554,151 A 9/1996 Hinchliffe
5,558,133 A 9/1996 Bortoli et al.
5,562,693 A 10/1996 Devlin et al.
5,569,243 A 10/1996 Kortenbach et al.
5,569,298 A 10/1996 Schnell
5,573,540 A 11/1996 Yoon
5,578,030 A 11/1996 Levin
5,582,611 A 12/1996 Tsuruta et al.
5,582,617 A 12/1996 Klieman et al.
5,584,845 A 12/1996 Hart
5,591,179 A 1/1997 Edelstein
5,593,420 A 1/1997 Eubanks, Jr. et al.
5,595,562 A 1/1997 Grier
5,597,378 A 1/1997 Jervis
5,601,573 A 2/1997 Fogelberg et al.
5,601,588 A 2/1997 Tonomura et al.
5,604,531 A 2/1997 Iddan et al.
5,607,389 A 3/1997 Edwards et al.
5,607,450 A 3/1997 Zvenyatsky et al.
5,613,975 A 3/1997 Christy
5,618,303 A 4/1997 Marlow et al.
5,620,415 A 4/1997 Lucey et al.
5,624,399 A 4/1997 Ackerman
5,624,431 A 4/1997 Gerry et al.
5,628,732 A 5/1997 Antoon, Jr. et al.
5,630,782 A 5/1997 Adair
5,643,283 A 7/1997 Younker
5,643,292 A 7/1997 Hart
5,643,294 A 7/1997 Tovey et al.
5,645,083 A 7/1997 Essig et al.
5,649,372 A 7/1997 Souza
5,653,677 A 8/1997 Okada et al.
5,653,722 A 8/1997 Kieturakis
5,662,663 A 9/1997 Shallman
5,669,875 A 9/1997 van Eerdenburg
5,681,324 A 10/1997 Kammerer et al.
5,681,330 A 10/1997 Hughett et al.
5,685,820 A 11/1997 Riek et al.
5,690,656 A 11/1997 Cope et al.
5,690,660 A 11/1997 Kauker et al.
5,695,448 A 12/1997 Kimura et al.
5,695,505 A 12/1997 Yoon
5,695,511 A 12/1997 Cano et al.
5,700,275 A 12/1997 Bell et al.
5,709,708 A 1/1998 Thal
5,716,326 A 2/1998 Dannan
5,730,740 A 3/1998 Wales et al.
5,741,278 A 4/1998 Stevens
5,741,285 A 4/1998 McBrayer et al.
5,746,759 A 5/1998 Meade et al.
5,749,881 A 5/1998 Sackier et al.
5,749,889 A 5/1998 Bacich et al.
5,752,951 A 5/1998 Yanik
5,766,167 A 6/1998 Eggers et al.
5,766,170 A 6/1998 Eggers
5,766,205 A 6/1998 Zvenyatsky et al.
5,769,849 A 6/1998 Eggers
5,779,701 A 7/1998 McBrayer et al.
5,779,716 A 7/1998 Cano et al.
5,779,727 A 7/1998 Orejola
5,782,859 A 7/1998 Nicholas et al.
5,782,866 A 7/1998 Wenstrom, Jr.
5,791,022 A 8/1998 Bohman
5,792,113 A 8/1998 Kramer et al.
5,792,153 A 8/1998 Swain et al.
5,792,165 A 8/1998 Klieman et al.
5,797,835 A 8/1998 Green
5,797,928 A 8/1998 Kogasaka
5,797,939 A 8/1998 Yoon
5,797,941 A 8/1998 Schulze et al.
5,803,903 A 9/1998 Athas et al.
5,808,665 A 9/1998 Green
5,810,806 A 9/1998 Ritchart et al.
5,810,849 A 9/1998 Kontos
5,810,865 A 9/1998 Koscher et al.
5,810,876 A 9/1998 Kelleher
5,810,877 A 9/1998 Roth et al.
5,813,976 A 9/1998 Filipi et al.
5,814,058 A 9/1998 Carlson et al.
5,817,061 A 10/1998 Goodwin et al.
5,817,107 A 10/1998 Schaller
5,817,119 A 10/1998 Klieman et al.
5,819,736 A 10/1998 Avny et al.
5,827,281 A 10/1998 Levin
5,827,299 A 10/1998 Thomason et al.
5,830,231 A 11/1998 Geiges, Jr.
5,833,700 A 11/1998 Fogelberg et al.
5,833,703 A 11/1998 Manushakian
5,843,017 A 12/1998 Yoon
5,849,022 A 12/1998 Sakashita et al.
5,853,374 A 12/1998 Hart et al.
5,855,585 A 1/1999 Kontos
5,860,913 A 1/1999 Yamaya et al.
5,860,995 A 1/1999 Berkelaar
5,868,762 A 2/1999 Cragg et al.
5,876,411 A 3/1999 Kontos
5,882,331 A 3/1999 Sasaki
5,882,344 A 3/1999 Stouder, Jr.
5,893,846 A 4/1999 Bales et al.
5,893,874 A 4/1999 Bourque et al.
5,893,875 A 4/1999 O'Connor et al.
5,899,919 A 5/1999 Eubanks, Jr. et al.
5,904,702 A 5/1999 Ek et al.
5,908,420 A 6/1999 Parins et al.
5,916,147 A 6/1999 Boury
5,921,993 A 7/1999 Yoon
5,921,997 A 7/1999 Fogelberg et al.
5,922,008 A 7/1999 Gimpelson
5,925,052 A 7/1999 Simmons
5,928,255 A 7/1999 Meade et al.
5,928,266 A 7/1999 Kontos
5,936,536 A 8/1999 Morris
5,944,718 A 8/1999 Austin et al.
5,951,549 A 9/1999 Richardson et al.
5,954,720 A 9/1999 Wilson et al.
5,954,731 A * 9/1999 Yoon 606/144
5,957,943 A 9/1999 Vaitekunas
5,957,953 A 9/1999 DiPoto et al.
5,971,995 A 10/1999 Rousseau
5,976,074 A 11/1999 Moriyama
5,976,075 A 11/1999 Beane et al.
5,976,130 A 11/1999 McBrayer et al.
5,976,131 A 11/1999 Guglielmi et al.
5,980,539 A 11/1999 Kontos
5,980,556 A 11/1999 Giordano et al.
5,984,938 A 11/1999 Yoon
5,989,182 A 11/1999 Hori et al.
5,993,447 A * 11/1999 Blewett et al. 606/50
5,997,555 A 12/1999 Kontos
6,001,120 A 12/1999 Levin
6,004,330 A 12/1999 Middleman et al.
6,007,566 A 12/1999 Wenstrom, Jr.
6,010,515 A 1/2000 Swain et al.
6,019,770 A 2/2000 Christoudias
6,024,708 A 2/2000 Bales et al.
6,024,747 A 2/2000 Kontos
6,027,522 A 2/2000 Palmer
6,030,365 A 2/2000 Laufer
6,033,399 A 3/2000 Gines
6,053,927 A 4/2000 Hamas
6,066,160 A 5/2000 Colvin et al.
6,068,603 A 5/2000 Suzuki
6,068,629 A 5/2000 Haissaguerre et al.

6,071,233 A 6/2000 Ishikawa et al.
6,074,408 A 6/2000 Freeman
6,086,530 A 7/2000 Mack
6,090,108 A 7/2000 McBrayer et al.
6,096,046 A 8/2000 Weiss
6,110,154 A 8/2000 Shimomura et al.
6,110,183 A 8/2000 Cope
6,117,144 A 9/2000 Nobles et al.
6,117,158 A 9/2000 Measamer et al.
6,139,555 A 10/2000 Hart et al.
6,146,391 A 11/2000 Cigaina
6,149,653 A 11/2000 Deslauriers
6,149,662 A 11/2000 Pugliesi et al.
6,159,200 A 12/2000 Verdura et al.
6,165,184 A 12/2000 Verdura et al.
6,168,570 B1 1/2001 Ferrera
6,168,605 B1 1/2001 Measamer et al.
6,170,130 B1 1/2001 Hamilton et al.
6,179,776 B1 1/2001 Adams et al.
6,179,837 B1 1/2001 Hooven
6,190,353 B1 2/2001 Makower et al.
6,190,384 B1 2/2001 Ouchi
6,190,399 B1 2/2001 Palmer et al.
6,203,533 B1 3/2001 Ouchi
6,206,872 B1 3/2001 Lafond et al.
6,206,877 B1 3/2001 Kese et al.
6,228,096 B1 5/2001 Marchand
6,245,079 B1 6/2001 Nobles et al.
6,258,064 B1 7/2001 Smith et al.
6,261,242 B1 7/2001 Roberts et al.
6,264,664 B1 7/2001 Avellanet
6,270,497 B1 8/2001 Sekino et al.
6,270,505 B1 8/2001 Yoshida et al.
6,277,136 B1 8/2001 Bonutti
6,283,963 B1 9/2001 Regula
6,293,909 B1 9/2001 Chu et al.
6,293,952 B1 9/2001 Brosens et al.
6,296,630 B1 10/2001 Altman et al.
6,322,578 B1 11/2001 Houle et al.
6,326,177 B1 12/2001 Schoenbach et al.
6,328,730 B1 12/2001 Harkrider, Jr.
6,350,267 B1 2/2002 Stefanchik
6,352,503 B1 3/2002 Matsui et al.
6,352,543 B1 3/2002 Cole
6,355,035 B1 3/2002 Manushakian
6,371,956 B1 4/2002 Wilson et al.
6,379,366 B1 4/2002 Fleischman et al.
6,383,195 B1 5/2002 Richard
6,383,197 B1 5/2002 Conlon et al.
6,391,029 B1 5/2002 Hooven et al.
6,406,440 B1 6/2002 Stefanchik
6,409,733 B1 6/2002 Conlon et al.
6,431,500 B1 8/2002 Jacobs et al.
6,447,511 B1 9/2002 Slater
6,447,523 B1 9/2002 Middleman et al.
6,454,783 B1 9/2002 Piskun
6,454,785 B2 9/2002 De Hoyos Garza
6,464,701 B1 10/2002 Hooven et al.
6,475,104 B1 11/2002 Lutz et al.
6,485,411 B1 11/2002 Konstorum et al.
6,489,745 B1 12/2002 Koreis
6,491,626 B1 12/2002 Stone et al.
6,491,691 B1 12/2002 Morley et al.
6,494,893 B2 12/2002 Dubrul et al.
6,503,192 B1 1/2003 Ouchi
6,506,190 B1 1/2003 Walshe
6,508,827 B1 1/2003 Manhes
6,543,456 B1 4/2003 Freeman
6,551,270 B1 4/2003 Bimbo et al.
6,554,829 B2 4/2003 Schulze et al.
6,558,384 B2 5/2003 Mayenberger
6,562,035 B1 5/2003 Levin
6,562,052 B2 5/2003 Nobles et al.
6,569,159 B1 5/2003 Edwards et al.
6,572,629 B2 6/2003 Kalloo et al.
6,572,635 B1 6/2003 Bonutti
6,575,988 B2 6/2003 Rousseau
6,585,642 B2 7/2003 Christopher
6,592,559 B1 7/2003 Pakter et al.
6,592,603 B2 7/2003 Lasner
6,602,262 B2 8/2003 Griego et al.
6,605,105 B1 8/2003 Cuschieri et al.
6,610,072 B1 8/2003 Christy et al.
6,610,074 B2 8/2003 Santilli
6,626,919 B1 9/2003 Swanstrom
6,632,229 B1 10/2003 Yamanouchi
6,638,286 B1 10/2003 Burbank et al.
6,652,521 B2 11/2003 Schulze
6,652,551 B1 11/2003 Heiss
6,656,194 B1 12/2003 Gannoe et al.
6,663,641 B1 12/2003 Kovac et al.
6,666,854 B1 12/2003 Lange
6,672,338 B1 1/2004 Esashi et al.
6,673,087 B1 1/2004 Chang et al.
6,685,628 B2 2/2004 Vu
6,685,724 B1 2/2004 Haluck
6,692,445 B2 * 2/2004 Roberts et al. 600/564
6,692,462 B2 2/2004 Mackenzie et al.
6,699,180 B2 3/2004 Kobayashi
6,699,256 B1 3/2004 Logan et al.
6,699,263 B2 3/2004 Cope
6,708,066 B2 3/2004 Herbst et al.
6,716,226 B2 4/2004 Sixto, Jr. et al.
6,740,030 B2 5/2004 Martone et al.
6,743,240 B2 6/2004 Smith et al.
6,749,560 B1 6/2004 Konstorum et al.
6,749,609 B1 6/2004 Lunsford et al.
6,752,768 B2 6/2004 Burdorff et al.
6,752,811 B2 6/2004 Chu et al.
6,752,822 B2 6/2004 Jespersen
6,761,685 B2 7/2004 Adams et al.
6,761,718 B2 7/2004 Madsen
6,761,722 B2 7/2004 Cole et al.
6,773,434 B2 8/2004 Ciarrocca
6,780,151 B2 8/2004 Grabover et al.
6,780,352 B2 8/2004 Jacobson
6,783,491 B2 8/2004 Saadat et al.
6,786,864 B2 9/2004 Matsuura et al.
6,790,173 B2 9/2004 Saadat et al.
6,795,728 B2 9/2004 Chornenky et al.
6,800,056 B2 10/2004 Tartaglia et al.
6,808,491 B2 10/2004 Kortenbach et al.
6,824,548 B2 11/2004 Smith et al.
6,837,847 B2 1/2005 Ewers et al.
6,843,794 B2 1/2005 Sixto, Jr. et al.
6,861,250 B1 3/2005 Cole et al.
6,866,627 B2 3/2005 Nozue
6,878,106 B1 4/2005 Herrmann
6,878,110 B2 4/2005 Yang et al.
6,884,213 B2 4/2005 Raz et al.
6,887,255 B2 5/2005 Shimm
6,896,683 B1 5/2005 Gadberry et al.
6,908,427 B2 6/2005 Fleener et al.
6,908,476 B2 6/2005 Jud et al.
6,916,284 B2 7/2005 Moriyama
6,918,871 B2 7/2005 Schulze
6,926,725 B2 8/2005 Cooke et al.
6,932,810 B2 8/2005 Ryan
6,932,824 B1 8/2005 Roop et al.
6,932,827 B2 8/2005 Cole
6,932,834 B2 8/2005 Lizardi et al.
6,942,613 B2 9/2005 Ewers et al.
6,945,472 B2 9/2005 Wuttke et al.
6,945,979 B2 9/2005 Kortenbach et al.
6,955,683 B2 10/2005 Bonutti
6,958,035 B2 10/2005 Friedman et al.
6,960,162 B2 11/2005 Saadat et al.
6,960,163 B2 11/2005 Ewers et al.
6,962,587 B2 11/2005 Johnson et al.
6,964,662 B2 11/2005 Kidooka
6,966,909 B2 11/2005 Marshall et al.
6,966,919 B2 11/2005 Sixto, Jr. et al.
6,967,462 B1 11/2005 Landis
6,971,988 B2 12/2005 Orban, III
6,972,017 B2 12/2005 Smith et al.
6,974,411 B2 12/2005 Belson
6,976,992 B2 12/2005 Sachatello et al.
6,984,203 B2 1/2006 Tartaglia et al.

6,984,205 B2 1/2006 Gazdzinski
6,986,774 B2 1/2006 Middleman et al.
6,988,987 B2 1/2006 Ishikawa et al.
6,991,627 B2 1/2006 Madhani et al.
6,994,708 B2 2/2006 Manzo
6,997,931 B2 2/2006 Sauer et al.
7,000,818 B2 2/2006 Shelton, IV et al.
7,008,375 B2 3/2006 Weisel
7,009,634 B2 3/2006 Iddan et al.
7,010,340 B2 3/2006 Scarantino et al.
7,020,531 B1 3/2006 Colliou et al.
7,025,580 B2 4/2006 Heagy et al.
7,029,435 B2 4/2006 Nakao
7,029,438 B2 4/2006 Morin et al.
7,037,290 B2 5/2006 Gardeski et al.
7,041,052 B2 5/2006 Saadat et al.
7,052,489 B2 5/2006 Griego et al.
7,060,024 B2 6/2006 Long et al.
7,060,025 B2 6/2006 Long et al.
7,063,697 B2 6/2006 Slater
7,063,715 B2 6/2006 Onuki et al.
7,066,879 B2 6/2006 Fowler et al.
7,066,936 B2 6/2006 Ryan
7,070,602 B2 7/2006 Smith et al.
7,076,305 B2 7/2006 Imran et al.
7,083,629 B2 8/2006 Weller et al.
7,087,071 B2 8/2006 Nicholas et al.
7,090,673 B2 8/2006 Dycus et al.
7,090,685 B2 8/2006 Kortenbach et al.
7,093,518 B2 8/2006 Gmeilbauer
7,101,371 B2 9/2006 Dycus et al.
7,101,372 B2 9/2006 Dycus et al.
7,101,373 B2 9/2006 Dycus et al.
7,105,000 B2 9/2006 McBrayer
7,105,005 B2 9/2006 Blake
7,108,703 B2 9/2006 Danitz et al.
7,112,208 B2 9/2006 Morris et al.
7,118,531 B2 10/2006 Krill
7,118,578 B2 10/2006 West, Jr. et al.
7,118,587 B2 10/2006 Dycus et al.
7,128,708 B2 10/2006 Saadat et al.
RE39,415 E 11/2006 Bales et al.
7,131,978 B2 11/2006 Sancoff et al.
7,131,979 B2 11/2006 DiCarlo et al.
7,131,980 B1 11/2006 Field et al.
7,137,980 B2 11/2006 Buysse et al.
7,137,981 B2 11/2006 Long
7,146,984 B2 12/2006 Stack et al.
7,147,650 B2 12/2006 Lee
7,153,321 B2 12/2006 Andrews
7,163,525 B2 1/2007 Franer
7,172,714 B2 2/2007 Jacobson
7,179,254 B2 2/2007 Pendekanti et al.
7,195,612 B2 3/2007 Van Sloten et al.
7,195,631 B2 3/2007 Dumbauld
7,208,005 B2 4/2007 Frecker et al.
7,211,092 B2 5/2007 Hughett
7,223,272 B2 5/2007 Francere et al.
7,232,414 B2 6/2007 Gonzalez
7,232,445 B2 6/2007 Kortenbach et al.
7,241,290 B2 7/2007 Doyle et al.
7,244,228 B2 7/2007 Lubowski
7,252,660 B2 8/2007 Kunz
7,270,663 B2 9/2007 Nakao
7,294,139 B1 11/2007 Gengler
7,301,250 B2 11/2007 Cassel
7,306,597 B2 12/2007 Manzo
7,318,802 B2 1/2008 Suzuki et al.
7,320,695 B2 1/2008 Carroll
7,322,934 B2 1/2008 Miyake et al.
7,329,257 B2 2/2008 Kanehira et al.
7,329,383 B2 2/2008 Stinson
7,344,536 B1 3/2008 Lunsford et al.
7,364,582 B2 4/2008 Lee
7,371,215 B2 5/2008 Colliou et al.
7,381,216 B2 6/2008 Buzzard et al.
7,393,222 B2 7/2008 Wenchell
7,402,162 B2 7/2008 Ouchi
7,404,791 B2 7/2008 Linares et al.
7,416,554 B2 8/2008 Lam et al.
7,422,590 B2 9/2008 Kupferschmid et al.
7,455,208 B2 11/2008 Wales et al.
7,488,295 B2 2/2009 Burbank et al.
7,497,867 B2 3/2009 Lasner et al.
7,507,200 B2 3/2009 Okada
7,524,281 B2 4/2009 Chu et al.
7,534,228 B2 5/2009 Williams
7,544,203 B2 6/2009 Chin et al.
7,548,040 B2 6/2009 Lee et al.
7,549,564 B2 6/2009 Boudreaux
7,553,278 B2 6/2009 Kucklick
7,553,298 B2 6/2009 Hunt et al.
7,559,887 B2 7/2009 Dannan
7,561,916 B2 7/2009 Hunt et al.
7,566,334 B2 7/2009 Christian et al.
7,579,550 B2 8/2009 Dayton et al.
7,582,096 B2 9/2009 Gellman et al.
7,651,483 B2 1/2010 Byrum et al.
7,651,509 B2 1/2010 Bojarski et al.
7,654,431 B2 2/2010 Hueil et al.
7,655,004 B2 2/2010 Long
7,662,089 B2 2/2010 Okada et al.
7,666,180 B2 2/2010 Holsten et al.
7,713,270 B2 5/2010 Suzuki
7,736,374 B2 6/2010 Vaughan et al.
7,762,998 B2 7/2010 Birk et al.
7,780,683 B2 8/2010 Roue et al.
7,794,475 B2 9/2010 Hess et al.
7,850,660 B2 12/2010 Uth et al.
7,862,546 B2 1/2011 Conlon et al.
7,918,869 B2 4/2011 Saadat et al.
2001/0049497 A1 12/2001 Kalloo et al.
2002/0022857 A1 2/2002 Goldsteen et al.
2002/0023353 A1 2/2002 Ting-Kung
2002/0042562 A1 4/2002 Meron et al.
2002/0049439 A1 4/2002 Mulier et al.
2002/0068945 A1 6/2002 Sixto, Jr. et al.
2002/0078967 A1 6/2002 Sixto, Jr. et al.
2002/0082516 A1 6/2002 Stefanchik
2002/0095164 A1 7/2002 Andreas et al.
2002/0107530 A1 8/2002 Sauer et al.
2002/0133115 A1 9/2002 Gordon et al.
2002/0138086 A1 9/2002 Sixto, Jr. et al.
2002/0147456 A1 10/2002 Diduch et al.
2002/0183591 A1 12/2002 Matsuura et al.
2003/0036679 A1 2/2003 Kortenbach et al.
2003/0069602 A1 4/2003 Jacobs et al.
2003/0114732 A1 6/2003 Webler et al.
2003/0130564 A1 7/2003 Martone et al.
2003/0130656 A1 7/2003 Levin
2003/0158521 A1 8/2003 Ameri
2003/0167062 A1 9/2003 Gambale et al.
2003/0171651 A1 9/2003 Page et al.
2003/0176880 A1 9/2003 Long et al.
2003/0216611 A1 11/2003 Vu
2003/0216615 A1 11/2003 Ouchi
2003/0220545 A1 11/2003 Ouchi
2003/0225312 A1 12/2003 Suzuki et al.
2003/0225332 A1 12/2003 Okada et al.
2003/0229269 A1 12/2003 Humphrey
2003/0229371 A1 12/2003 Whitworth
2003/0236549 A1 12/2003 Bonadio et al.
2004/0098007 A1 5/2004 Heiss
2004/0101456 A1 5/2004 Kuroshima et al.
2004/0116948 A1 6/2004 Sixto, Jr. et al.
2004/0133089 A1 7/2004 Kilcoyne et al.
2004/0136779 A1 7/2004 Bhaskar
2004/0138525 A1 7/2004 Saadat et al.
2004/0138529 A1 7/2004 Wiltshire et al.
2004/0138587 A1 7/2004 Lyons, IV
2004/0186350 A1 9/2004 Brenneman et al.
2004/0193009 A1 9/2004 Jaffe et al.
2004/0193146 A1 9/2004 Lee et al.
2004/0193186 A1 9/2004 Kortenbach et al.
2004/0193188 A1 9/2004 Francese
2004/0193189 A1 9/2004 Kortenbach et al.
2004/0193200 A1 9/2004 Dworschak et al.
2004/0199052 A1 10/2004 Banik et al.

2004/0210245 A1 10/2004 Erickson et al.
2004/0215058 A1 10/2004 Zirps et al.
2004/0225183 A1 11/2004 Michlitsch et al.
2004/0225186 A1 11/2004 Horne, Jr. et al.
2004/0230095 A1 11/2004 Stefanchik et al.
2004/0230096 A1 11/2004 Stefanchik et al.
2004/0230097 A1 11/2004 Stefanchik et al.
2004/0230161 A1 11/2004 Zeiner
2004/0249246 A1 12/2004 Campos
2004/0249367 A1 12/2004 Saadat et al.
2004/0249394 A1 12/2004 Morris et al.
2005/0033277 A1 2/2005 Clague et al.
2005/0033319 A1 2/2005 Gambale et al.
2005/0033333 A1 2/2005 Smith et al.
2005/0043690 A1 2/2005 Todd
2005/0049616 A1 3/2005 Rivera et al.
2005/0065397 A1 3/2005 Saadat et al.
2005/0065517 A1 3/2005 Chin
2005/0070754 A1 3/2005 Nobis et al.
2005/0070763 A1 3/2005 Nobis et al.
2005/0070764 A1 3/2005 Nobis et al.
2005/0080413 A1 4/2005 Canady
2005/0085693 A1 4/2005 Belson et al.
2005/0085832 A1 4/2005 Sancoff et al.
2005/0090837 A1 4/2005 Sixto, Jr. et al.
2005/0090838 A1 4/2005 Sixto, Jr. et al.
2005/0101837 A1 5/2005 Kalloo et al.
2005/0101838 A1 5/2005 Camillocci et al.
2005/0107663 A1 5/2005 Saadat et al.
2005/0107664 A1 5/2005 Kalloo et al.
2005/0110881 A1 5/2005 Glukhovsky et al.
2005/0113847 A1 5/2005 Gadberry et al.
2005/0124855 A1 6/2005 Jaffe et al.
2005/0125010 A1 6/2005 Smith et al.
2005/0131279 A1 6/2005 Boulais et al.
2005/0131457 A1 6/2005 Douglas et al.
2005/0137454 A1 6/2005 Saadat et al.
2005/0143690 A1 6/2005 High
2005/0143774 A1 6/2005 Polo
2005/0149087 A1 7/2005 Ahlberg et al.
2005/0149096 A1 7/2005 Hilal et al.
2005/0159648 A1 7/2005 Freed
2005/0165272 A1 7/2005 Okada et al.
2005/0165378 A1 7/2005 Heinrich et al.
2005/0165411 A1 7/2005 Orban, III
2005/0165429 A1 7/2005 Douglas et al.
2005/0192598 A1 9/2005 Johnson et al.
2005/0192602 A1 9/2005 Manzo
2005/0192654 A1 9/2005 Chanduszko et al.
2005/0209624 A1 9/2005 Vijay
2005/0215858 A1 9/2005 Vail, III
2005/0216050 A1 9/2005 Sepetka et al.
2005/0228406 A1 10/2005 Bose
2005/0234297 A1 10/2005 Devierre et al.
2005/0250990 A1 11/2005 Le et al.
2005/0251176 A1 11/2005 Swanstrom et al.
2005/0261674 A1 11/2005 Nobis et al.
2005/0267492 A1 12/2005 Poncet et al.
2005/0272975 A1 12/2005 McWeeney et al.
2005/0272977 A1 12/2005 Saadat et al.
2005/0273084 A1 12/2005 Hinman et al.
2005/0277945 A1 12/2005 Saadat et al.
2005/0277951 A1 12/2005 Smith et al.
2005/0277952 A1 12/2005 Arp et al.
2005/0277954 A1 12/2005 Smith et al.
2005/0277955 A1 12/2005 Palmer et al.
2005/0277956 A1 12/2005 Francese et al.
2005/0277957 A1 12/2005 Kuhns et al.
2005/0283118 A1 12/2005 Uth et al.
2005/0283119 A1 12/2005 Uth et al.
2005/0288555 A1 12/2005 Binmoeller
2006/0004406 A1 1/2006 Wehrstein et al.
2006/0004409 A1 1/2006 Nobis et al.
2006/0004410 A1 1/2006 Nobis et al.
2006/0015009 A1 1/2006 Jaffe et al.
2006/0020167 A1 1/2006 Sitzmann
2006/0020247 A1 1/2006 Kagan et al.
2006/0025654 A1 2/2006 Suzuki et al.
2006/0025781 A1 2/2006 Young et al.
2006/0025819 A1 2/2006 Nobis et al.
2006/0036267 A1 2/2006 Saadat et al.
2006/0041188 A1 2/2006 Dirusso et al.
2006/0058582 A1 3/2006 Maahs et al.
2006/0058776 A1 3/2006 Bilsbury
2006/0069396 A1 3/2006 Meade et al.
2006/0079890 A1 4/2006 Guerra
2006/0089528 A1 4/2006 Tartaglia et al.
2006/0095060 A1 5/2006 Mayenberger et al.
2006/0106423 A1 5/2006 Weisel et al.
2006/0111209 A1 5/2006 Hinman et al.
2006/0111210 A1 5/2006 Hinman et al.
2006/0111704 A1 5/2006 Brenneman et al.
2006/0129166 A1 6/2006 Lavelle
2006/0135962 A1 6/2006 Kick et al.
2006/0135971 A1 6/2006 Swanstrom et al.
2006/0135984 A1 6/2006 Kramer et al.
2006/0142644 A1 6/2006 Mulac et al.
2006/0142652 A1 6/2006 Keenan
2006/0142790 A1 6/2006 Gertner
2006/0142798 A1 6/2006 Holman et al.
2006/0149132 A1 7/2006 Iddan
2006/0149135 A1 7/2006 Paz
2006/0161190 A1 7/2006 Gadberry et al.
2006/0167416 A1 7/2006 Mathis et al.
2006/0167482 A1 7/2006 Swain et al.
2006/0178560 A1 8/2006 Saadat et al.
2006/0183975 A1 8/2006 Saadat et al.
2006/0184161 A1 8/2006 Maahs et al.
2006/0189844 A1 8/2006 Tien
2006/0189845 A1 8/2006 Maahs et al.
2006/0190027 A1 8/2006 Downey
2006/0195084 A1 8/2006 Slater
2006/0200005 A1 9/2006 Bjork et al.
2006/0200169 A1 9/2006 Sniffin
2006/0200170 A1 9/2006 Aranyi
2006/0200199 A1 9/2006 Bonutti et al.
2006/0217697 A1 9/2006 Lau et al.
2006/0217742 A1 9/2006 Messerly et al.
2006/0217743 A1 9/2006 Messerly et al.
2006/0229639 A1 10/2006 Whitfield
2006/0229640 A1 10/2006 Whitfield
2006/0237022 A1 10/2006 Chen et al.
2006/0237023 A1 10/2006 Cox et al.
2006/0241570 A1 10/2006 Wilk
2006/0247673 A1 11/2006 Voegele et al.
2006/0253004 A1 11/2006 Frisch et al.
2006/0253039 A1 11/2006 McKenna et al.
2006/0258907 A1 11/2006 Stefanchik et al.
2006/0258908 A1 11/2006 Stefanchik et al.
2006/0258910 A1 11/2006 Stefanchik et al.
2006/0258954 A1 11/2006 Timberlake et al.
2006/0258955 A1 11/2006 Hoffman et al.
2006/0259010 A1 11/2006 Stefanchik et al.
2006/0264752 A1* 11/2006 Rubinsky et al. 600/439
2006/0264930 A1 11/2006 Nishimura
2006/0270902 A1 11/2006 Igarashi et al.
2006/0271102 A1 11/2006 Bosshard et al.
2006/0276835 A1 12/2006 Uchida
2006/0281970 A1 12/2006 Stokes et al.
2006/0285732 A1 12/2006 Horn et al.
2006/0287644 A1 12/2006 Inganas et al.
2006/0287666 A1 12/2006 Saadat et al.
2006/0293626 A1 12/2006 Byrum et al.
2007/0002135 A1 1/2007 Glukhovsky
2007/0005019 A1 1/2007 Okishige
2007/0015965 A1 1/2007 Cox et al.
2007/0016255 A1 1/2007 Nakao
2007/0032700 A1 2/2007 Fowler et al.
2007/0032701 A1 2/2007 Fowler et al.
2007/0043345 A1 2/2007 Davalos et al.
2007/0049800 A1 3/2007 Boulais
2007/0051375 A1 3/2007 Milliman
2007/0060880 A1 3/2007 Gregorich et al.
2007/0073102 A1 3/2007 Matsuno et al.
2007/0079924 A1 4/2007 Saadat et al.
2007/0088370 A1 4/2007 Kahle et al.
2007/0100375 A1 5/2007 Mikkaichi et al.
2007/0100376 A1 5/2007 Mikkaichi et al.

2007/0106118 A1 5/2007 Moriyama
2007/0112251 A1 5/2007 Nakhuda
2007/0112331 A1 5/2007 Weber et al.
2007/0112342 A1 5/2007 Pearson et al.
2007/0112383 A1 5/2007 Conlon et al.
2007/0112384 A1 5/2007 Conlon et al.
2007/0112385 A1 5/2007 Conlon
2007/0112425 A1 5/2007 Schaller et al.
2007/0118115 A1 5/2007 Artale et al.
2007/0122425 A1 5/2007 Schaller et al.
2007/0123840 A1 5/2007 Cox
2007/0129719 A1 6/2007 Kendale et al.
2007/0135709 A1 6/2007 Rioux et al.
2007/0156127 A1 7/2007 Rioux et al.
2007/0161855 A1 7/2007 Mikkaichi et al.
2007/0173869 A1 7/2007 Gannoe et al.
2007/0173870 A2 7/2007 Zacharias
2007/0173872 A1 7/2007 Neuenfeldt
2007/0179525 A1 8/2007 Frecker et al.
2007/0179530 A1 8/2007 Tieu et al.
2007/0197865 A1 8/2007 Miyake et al.
2007/0203487 A1 8/2007 Sugita
2007/0208364 A1 9/2007 Smith et al.
2007/0213754 A1 9/2007 Mikkaichi et al.
2007/0225554 A1 9/2007 Maseda et al.
2007/0233040 A1 10/2007 Macnamara et al.
2007/0244358 A1 10/2007 Lee
2007/0250057 A1 10/2007 Nobis et al.
2007/0255096 A1 11/2007 Stefanchik et al.
2007/0255100 A1 11/2007 Barlow et al.
2007/0255273 A1 11/2007 Fernandez et al.
2007/0255303 A1 11/2007 Bakos et al.
2007/0255306 A1 11/2007 Conlon et al.
2007/0260112 A1 11/2007 Rahmani
2007/0260117 A1 11/2007 Zwolinski et al.
2007/0260121 A1 11/2007 Bakos et al.
2007/0260273 A1 11/2007 Cropper et al.
2007/0270629 A1 11/2007 Charles
2007/0270889 A1 11/2007 Conlon et al.
2007/0270895 A1 11/2007 Nobis et al.
2007/0270907 A1 11/2007 Stokes et al.
2007/0282371 A1 12/2007 Lee et al.
2008/0004650 A1 1/2008 George
2008/0015409 A1 1/2008 Barlow et al.
2008/0015552 A1 1/2008 Doyle et al.
2008/0027387 A1 1/2008 Grabinsky
2008/0033451 A1 2/2008 Rieber et al.
2008/0051629 A1 2/2008 Sugiyama et al.
2008/0051735 A1 2/2008 Measamer et al.
2008/0058586 A1 3/2008 Karpiel
2008/0065169 A1 3/2008 Colliou et al.
2008/0086172 A1 4/2008 Martin et al.
2008/0097472 A1 4/2008 Agmon et al.
2008/0097483 A1 4/2008 Ortiz et al.
2008/0103527 A1 5/2008 Martin et al.
2008/0114384 A1 5/2008 Chang et al.
2008/0119870 A1 5/2008 Williams
2008/0125796 A1 5/2008 Graham
2008/0132892 A1 6/2008 Lunsford et al.
2008/0139882 A1 6/2008 Fujimori
2008/0147113 A1 6/2008 Nobis et al.
2008/0171907 A1 7/2008 Long et al.
2008/0200755 A1 8/2008 Bakos
2008/0200762 A1 8/2008 Stokes et al.
2008/0200911 A1 8/2008 Long
2008/0200933 A1 8/2008 Bakos et al.
2008/0200934 A1 8/2008 Fox
2008/0208213 A1 8/2008 Benjamin et al.
2008/0221587 A1 9/2008 Schwartz
2008/0221619 A1 9/2008 Spivey et al.
2008/0228213 A1 9/2008 Blakeney et al.
2008/0230972 A1 9/2008 Ganley
2008/0234696 A1 9/2008 Taylor et al.
2008/0243106 A1 10/2008 Coe et al.
2008/0243148 A1 10/2008 Mikkaichi et al.
2008/0243176 A1 10/2008 Weitzner et al.
2008/0262540 A1 10/2008 Bangera et al.
2008/0269782 A1 10/2008 Stefanchik et al.
2008/0269783 A1 10/2008 Griffith
2008/0275474 A1 11/2008 Martin et al.
2008/0275475 A1 11/2008 Schwemberger et al.
2008/0300547 A1 12/2008 Bakos
2008/0309758 A1 12/2008 Karasawa et al.
2008/0312496 A1 12/2008 Zwolinski
2008/0312499 A1 12/2008 Handa et al.
2008/0312500 A1 12/2008 Asada et al.
2008/0312506 A1 12/2008 Spivey et al.
2008/0319436 A1 12/2008 Daniel et al.
2009/0054728 A1 2/2009 Trusty
2009/0062788 A1 3/2009 Long et al.
2009/0062792 A1 3/2009 Vakharia et al.
2009/0062795 A1 3/2009 Vakharia et al.
2009/0082776 A1 3/2009 Cresina
2009/0082779 A1 3/2009 Nakao
2009/0112059 A1 4/2009 Nobis
2009/0112062 A1 4/2009 Bakos
2009/0112063 A1 4/2009 Bakos et al.
2009/0131751 A1 5/2009 Spivey et al.
2009/0131932 A1 5/2009 Vakharia et al.
2009/0131933 A1 5/2009 Ghabrial et al.
2009/0143639 A1 6/2009 Stark
2009/0143794 A1 6/2009 Conlon et al.
2009/0149710 A1 6/2009 Stefanchik et al.
2009/0177031 A1 7/2009 Surti et al.
2009/0177219 A1 7/2009 Conlon
2009/0182332 A1 7/2009 Long et al.
2009/0192344 A1 7/2009 Bakos et al.
2009/0198231 A1 8/2009 Esser et al.
2009/0227828 A1 9/2009 Swain et al.
2009/0248055 A1 10/2009 Spivey et al.
2009/0281559 A1 11/2009 Swain et al.
2009/0287236 A1 11/2009 Bakos et al.
2009/0292164 A1 11/2009 Yamatani
2009/0299135 A1 12/2009 Spivey
2009/0299143 A1 12/2009 Conlon et al.
2009/0299362 A1 12/2009 Long et al.
2009/0299385 A1 12/2009 Stefanchik et al.
2009/0299406 A1 12/2009 Swain et al.
2009/0299409 A1 12/2009 Coe et al.
2009/0306658 A1 12/2009 Nobis et al.
2009/0306683 A1 12/2009 Zwolinski et al.
2009/0322864 A1 12/2009 Karasawa et al.
2009/0326561 A1 12/2009 Carroll, II et al.
2010/0010294 A1 1/2010 Conlon et al.
2010/0010298 A1 1/2010 Bakos et al.
2010/0010299 A1 1/2010 Bakos et al.
2010/0010303 A1 1/2010 Bakos
2010/0010510 A1 1/2010 Stefanchik
2010/0010511 A1 1/2010 Harris et al.
2010/0042045 A1 2/2010 Spivey
2010/0048990 A1 2/2010 Bakos
2010/0049190 A1 2/2010 Long et al.
2010/0056861 A1 3/2010 Spivey
2010/0056862 A1 3/2010 Bakos
2010/0057085 A1 3/2010 Holcomb et al.
2010/0057108 A1 3/2010 Spivey et al.
2010/0063538 A1 3/2010 Spivey et al.
2010/0076451 A1 3/2010 Zwolinski et al.
2010/0081877 A1 4/2010 Vakharia
2010/0113872 A1 5/2010 Asada et al.
2010/0121362 A1 5/2010 Clague et al.
2010/0130817 A1 5/2010 Conlon
2010/0130975 A1 5/2010 Long
2010/0131005 A1 5/2010 Conlon
2010/0152539 A1 6/2010 Ghabrial et al.
2010/0152609 A1 6/2010 Zwolinski et al.
2010/0152746 A1 6/2010 Ceniccola et al.
2010/0179510 A1 7/2010 Fox et al.
2010/0179530 A1 7/2010 Long et al.
2010/0191050 A1 7/2010 Zwolinski
2010/0191267 A1 7/2010 Fox
2010/0198005 A1 8/2010 Fox
2010/0198149 A1 8/2010 Fox
2010/0198244 A1 8/2010 Spivey et al.
2010/0198248 A1 8/2010 Vakharia
2010/0286791 A1 11/2010 Goldsmith
2010/0298642 A1 11/2010 Trusty et al.
2010/0331622 A2 12/2010 Conlon

2010/0331774	A2	12/2010	Spivey
2011/0093009	A1	4/2011	Fox
2011/0098694	A1	4/2011	Long
2011/0098704	A1	4/2011	Long et al.
2011/0105850	A1	5/2011	Voegele et al.
2011/0112434	A1	5/2011	Ghabrial et al.

FOREIGN PATENT DOCUMENTS

DE	4323585	A1	1/1995
DE	19757056	B4	8/2008
DE	102006027873	B4	10/2009
EP	0086338	A1	8/1983
EP	0286415	A2	10/1988
EP	0589454	A2	3/1994
EP	0464479	B1	3/1995
EP	0529675	B1	2/1996
EP	0724863	B1	7/1999
EP	0760629	B1	11/1999
EP	0818974	B1	7/2001
EP	0947166	B1	5/2003
EP	0836832	B1	12/2003
EP	1402837	A1	3/2004
EP	0744918	B1	4/2004
EP	0931515	B1	8/2004
EP	1411843	B1	10/2004
EP	1150614	B1	11/2004
EP	1477104	A1	11/2004
EP	1481642	A1	12/2004
EP	1493391	A1	1/2005
EP	0848598	B1	2/2005
EP	1281360	B1	3/2005
EP	1568330	A1	8/2005
EP	1452143	B1	9/2005
EP	1616527	A2	1/2006
EP	1006888	B1	3/2006
EP	1629764	A1	3/2006
EP	1013229	B1	6/2006
EP	1721561	A1	11/2006
EP	1153578	B1	3/2007
EP	1334696	B1	3/2007
EP	1769766	A1	4/2007
EP	1836971	A2	9/2007
EP	1836980	A1	9/2007
EP	1854421	A2	11/2007
EP	1857061	A1	11/2007
EP	1875876	A1	1/2008
EP	1891881	A1	2/2008
EP	1902663	A1	3/2008
EP	1477106	B1	6/2008
EP	1949844	A1	7/2008
EP	1518499	B1	8/2008
EP	1709918	B1	10/2008
EP	1985226	A2	10/2008
EP	1994904	A1	11/2008
EP	1707130	B1	12/2008
EP	1769749	B1	11/2009
FR	2731610	A1	9/1996
GB	2403909	A	1/2005
GB	2443261	A	4/2008
JP	56-46674		4/1981
JP	8-29699	A	2/1996
JP	2002-369791	A	12/2002
JP	2003-088494	A	3/2003
JP	2003-235852	A	8/2003
JP	2004-33525	A	2/2004
JP	2004-065745	A	3/2004
JP	2005-121947	A	5/2005
JP	2005-261514	A	9/2005
NL	1021295	C2	2/2004
SU	194230		5/1967
SU	980703		12/1982
WO	WO 84/01707	A1	5/1984
WO	WO 92/13494	A1	8/1992
WO	WO 93/10850	A1	6/1993
WO	WO 93/20760	A1	10/1993
WO	WO 93/20765	A1	10/1993
WO	WO 95/09666	A1	4/1995
WO	WO 96/22056	A1	7/1996
WO	WO 96/27331	A1	9/1996
WO	WO 96/39946	A1	12/1996
WO	WO 97/12557	A1	4/1997
WO	WO 98/01080	A1	1/1998
WO	WO 99/09919	A1	3/1999
WO	WO 99/17661	A1	4/1999
WO	WO 99/30622	A2	6/1999
WO	WO 01/10319	A1	2/2001
WO	WO 01/58360	A2	8/2001
WO	WO 02/11621	A1	2/2002
WO	WO 02/34122	A2	5/2002
WO	WO 02/094082	A2	11/2002
WO	WO 03/045260	A1	6/2003
WO	WO 03/047684	A2	6/2003
WO	WO 03/059412	A2	7/2003
WO	WO 03/078721	A2	9/2003
WO	WO 03/082129	A2	10/2003
WO	WO 2004/006789	A1	1/2004
WO	WO 2004/028613	A2	4/2004
WO	WO 2004/037123	A1	5/2004
WO	WO 2004/052221	A1	6/2004
WO	WO 2004/086984	A1	10/2004
WO	WO 2005/009211	A2	2/2005
WO	WO 2005/018467	A2	3/2005
WO	WO 2005/037088	A2	4/2005
WO	WO 2005/048827	A1	6/2005
WO	WO 2005/065284	A2	7/2005
WO	WO 2005/097019	A2	10/2005
WO	WO 2005/097234	A2	10/2005
WO	WO 2005/112810	A2	12/2005
WO	WO 2005/120363	A1	12/2005
WO	WO 2006/007399	A1	1/2006
WO	WO 2006/041881	A2	4/2006
WO	WO 2006/060405	A2	6/2006
WO	WO 2006/110733	A2	10/2006
WO	WO 2006/113216	A2	10/2006
WO	WO 2007/014063	A2	2/2007
WO	WO 2007/048085	A2	4/2007
WO	WO 2007/063550	A2	6/2007
WO	WO 2007/100067	A1	9/2007
WO	WO 2007/109171	A2	9/2007
WO	WO 2008/005433	A1	1/2008
WO	WO 2008/041225	A2	4/2008
WO	WO 2008/076337	A1	6/2008
WO	WO 2008/076800	A2	6/2008
WO	WO 2008/101075	A2	8/2008
WO	WO 2008/102154	A2	8/2008
WO	WO 2009/021030	A1	2/2009
WO	WO 2009/027065	A1	3/2009
WO	WO 2009/029065	A1	3/2009
WO	WO 2009/032623	A2	3/2009
WO	WO 2010/088481	A1	8/2010

OTHER PUBLICATIONS

Ethicon, Inc., "Wound Closure Manual: Chapter 3 (The Surgical Needle)," 15 pages, (1994).

Guido M. Sclabas, M.D., et al., "Endoluminal Methods for Gastrotomy Closure in Natural Orifice TransEnteric Surgery (NOTES)," Surgical Innovation, vol. 13, No. 1, pp. 23-30, Mar. 2006.

Fritscher-Ravens, et al., "Transgastric Gastropexy and Hiatal Hernia Repair for GERD Under EUS Control: a Porcine Model," Gastrointestinal Endoscopy, vol. 59, No. 1, pp. 89-95, 2004.

Ogando, "Prototype Tools That Go With the Flow," Design News, 2 pages, Jul. 17, 2006.

Edd, et al., "In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation," IEEE Trans Biomed Eng, vol. 53, pp. 1409-1415, 2006.

Kennedy, et al., "High-Burst-Strength, Feedback-Controlled Bipolar Vessel Sealing," Surgical Endoscopy, vol. 12, pp. 876-878 (1998).

Collins et al., "Local Gene Therapy of Solid Tumors with GM-CSF and B7-1 Eradicates Both Treated and Distal Tumors," Cancer Gene Therapy, vol. 13, pp. 1061-1071 (2006).

K. Sumiyama et al., "Transesophageal Mediastinoscopy by Submucosal Endoscopy With Mucosal Flap Safety Value Technique," Gastrointest Endosc., Apr. 2007, vol. 65(4), pp. 679-683 (Abstract).

K. Sumiyama et al., "Submucosal Endoscopy with Mucosal Flap Safety Valve," Gastrointest Endosc. Apr. 2007, vol. 65(4) pp. 694-695 (Abstract).

K. Sumiyama et al., "Transgastric Cholecystectomy: Transgastric Accessibility to the Gallbladder Improved with the SEMF Method and a Novel Multibending Therapeutic Endoscope," Gastrointest Endosc., Jun. 2007, vol. 65(7), pp. 1028-1034 (Abstract).
K. Sumiyama et al., "Endoscopic Caps," Tech. Gastrointest. Endosc., vol. 8, pp. 28-32, 2006.
"Z-Offset Technique Used in the Introduction of Trocar During Laparoscopic Surgery," M.S. Hershey NOTES Presentation to EES NOTES Development Team, Sep. 27, 2007.
F.N. Denans, Nouveau Procede Pour La Guerison Des Plaies Des Intestines. Extrait Des Seances De La Societe Royale De Medecine De Marseille, Pendant Le Mois De Decembre 1825, et le Premier Tremestre De 1826, Séance Du 24 Fevrier 1826. Recueil De La Societe Royale De Medecin De Marseille. Marseille: Impr. D'Achard, 1826; 1:127-31. (with English translation).
I. Fraser, "An Historical Perspective on Mechanical Aids in Intestinal Anastamosis," Surg. Gynecol. Obstet. (Oct. 1982), vol. 155, pp. 566-574.
M.E. Ryan et al., "Endoscopic Intervention for Biliary Leaks After Laparoscopic Cholecystectomy: A Multicenter Review," Gastrointest. Endosc., vol. 47(3), 1998, pp. 261-266.
C. Cope, "Creation of Compression Gastroenterostomy by Means of the Oral, Percutaneous, or Surgical Introduction of Magnets: Feasibility Study in Swine," J. Vasc Interv Radiol, (1995), vol. 6(4), pp. 539-545.
J.W. Hazey et al., "Natural Orifice Transgastric Endoscopic Peritoneoscopy in Humans: Initial Clinical Trial," Surg Endosc, (Jan. 2008), vol. 22(1), pp. 16-20.
N. Chopita et al., "Endoscopic Gastroenteric Anastamosis Using Magnets," Endoscopy, (2005), vol. 37(4), pp. 313-317.
C. Cope et al., "Long Term Patency of Experimental Magnetic Compression Gastroenteric Anastomoses Achieved with Covered Stents," Gastrointest Endosc, (2001), vol. 53, pp. 780-784.
H. Okajima et al., "Magnet Compression Anastamosis for Bile Duct Stenosis After Duct to Duct Biliary Reconstruction in Living Donor Liver Transplantation," Liver Transplantation (2005), pp. 473-475.
A. Fritscher-Ravens et al., "Transluminal Endosurgery: Single Lumen Access Anastamotic Device for Flexible Endoscopy," Gastrointestinal Endosc, (2003), vol. 58(4), pp. 585-591.
G.A. Hallenbeck, M.D. et al., "An Instrument for Colorectal Anastomosis Without Sutrues," Dis Col Rectum, (1963), vol. 5, pp. 98-101.
T. Hardy, Jr., M.D. et al., "A Biofragmentable Ring for Sutureless Bowel Anastomosis. An Experimental Study," Dis Col Rectum, (1985), vol. 28, pp. 484-490.
P. O'Neill, M.D. et al., "Nonsuture Intestinal Anastomosis," Am J. Surg, (1962), vol. 104, pp. 761-767.
C.P. Swain, M.D. et al., "Anastomosis at Flexible Endoscopy: An Experimental Study of Compression Button Gastrojejunostomy," Gastrointest Endosc, (1991), vol. 37, pp. 628-632.
J.B. Murphy, M.D., "Cholecysto-Intestinal, Gastro-Intestinal, Entero-Intestinal Anastomosis, and Approximation Without Sutures (original research)," Med Rec, (Dec. 10, 1892), vol. 42(24), pp. 665-676.
USGI® EndoSurgical Operating System—g-Prox® Tissue Grasper/Approximation Device; [online] URL:http://www.usgimedical.com/eos/components-gprox.htm—accessed May 30, 2008 (2 pages).
Printout of web page—http://www.vacumed.com/zcom/product/Product.do?compid=27&prodid=852, #51XX Low-Cost Permanent Tubes 2MM ID, Smooth Interior Walls, VacuMed, Ventura, California, Accessed Jul. 24, 2007.
Endoscopic Retrograde Cholangiopancreatogram (ERCP); [online] URL: http://www.webmd.com/digestive-disorders/endoscopic-retrograde-cholangiopancreatogram-ercp.htm; last updated: Apr. 30, 2007; accessed: Feb. 21, 2008 (6 pages).
ERCP; Jackson Siegelbaum Gastroenterology; [online] URL: http://www.gicare.com/pated/epdgs20.htm; accessed Feb. 21, 2008 (3 pages).
D.G. Fong et al., "Transcolonic Ventral Wall Hernia Mesh Fixation in a Porcine Model," Endoscopy 2007; 39: 865-869.
B. Rubinsky, Ph.D., "Irreversible Electroporation in Medicine," Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 2007, pp. 255-259.
D.B. Nelson, MD et al., "Endoscopic Hemostatic Devices," Gastrointestinal Endoscopy, vol. 54, No. 6, 2001, pp. 833-840.
CRE™ Pulmonary Balloon Dilator; [online] URL: http://www.bostonscientific.com/Device.bsci?page=HCP_Overview&navRe1Id=1000.1003&method=D..., accessed Jul. 18, 2008 (4 pages).
J.D. Paulson, M.D., et al., "Development of Flexible Culdoscopy," The Journal of the American Association of Gynecologic Laparoscopists, Nov. 1999, vol. 6, No. 4, pp. 487-490.
H. Seifert, et al., "Retroperitoneal Endoscopic Debridement for Infected Peripancreatic Necrosis," The Lancet, Research Letters, vol. 356, Aug. 19, 2000, pp. 653-655.
K.E. Mönkemüller, M.D., et al., "Transmural Drainage of Pancreatic Fluid Collections Without Electrocautery Using the Seldinger Technique," Gastrointestinal Endoscopy, vol. 48, No. 2, 1998, pp. 195-200, (Received Oct. 3, 1997; Accepted Mar. 31, 1998).
D. Wilhelm et al., "An Innovative, Safe and Sterile Sigmoid Access (ISSA) for NOTES," Endoscopy 2007, vol. 39, pp. 401-406.
Nakazawa et al., "Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin," AJR, 188, pp. 480-488 (Feb. 2007).
Miklavčič et al., "A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy," Biochimica et Biophysica Acta, 1523, pp. 73-83 (2000).
Evans, "Ablative and cathether-delivered therapies for colorectal liver metastases (CRLM)," EJSO, 33, pp. S64-S75 (2007).
Wong et al., "Combined Percutaneous Radiofrequency Ablation and Ethanol Injection for Hepatocellular Carcinoma in High-Risk Locations," AJR, 190, pp. W187-W195 (2008).
Heller et al., "Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo," Gene Therapy, 7, pp. 826-829 (2000).
Widera et al., "Increased DNA Vaccine Delivery and Immunogenicity by Electroporation in Vivo," The Journal of Immunology, 164, pp. 4635-4640 (2000).
Weaver et al., "Theory of electroporation: A review," Bioelectrochemistry and Bioenergetics, 41, pp. 135-160 (1996).
Mulier et al., "Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?" Annals of Surgical Oncology, 15(1), pp. 144-157 (2008).
Link et al., "Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxanthrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival," Cancer, 92, pp. 2746-2753 (2001).
Guyton et al., "Membrane Potentials and Action Potentials," W.B. Sanders, ed. Textbook of Medical Physiology, p. 56 (2000).
Guyton et al., "Contraction of Skeletal Muscle," Textbook of Medical Physiology, pp. 82-84 (2000).
"Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages," Apr. 22, 2009 Press Release; URL http://www.jnj.com/connect/news/all/20090422_152000; accessed Aug. 28, 2009 (3 pages).
"Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox," Jun. 3, 2009 Press Release; URL http://www.jnj.com/connect/news/product/20090603_120000; accessed Aug. 28, 2009 (3 pages).
Castellvi et al., "Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using A Magnetically Anchored Camera and Novel Instrumentation," Abstract submitted along with Poster at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
OCTO Port Modular Laparoscopy System for Single Incision Access, Jan. 4, 2010; URL http://www.medgadget.com/archives/2010/01/octo_port_modular_laparo...; accessed Jan. 5, 2010 (4 pages).
Hakko Retractors, obtained Aug. 25, 2009 (5 pages).
U.S. Appl. No. 12/413,479, filed Mar. 27, 2009.
U.S. Appl. No. 12/468,462, filed May 19, 2009.
U.S. Appl. No. 12/607,252, filed Oct. 28, 2009.
U.S. Appl. No. 12/580,400, filed Oct. 16, 2009.
U.S. Appl. No. 12/607,388, filed Oct. 28, 2009.
U.S. Appl. No. 12/612,911, filed Nov. 5, 2009.
U.S. Appl. No. 12/614,143, filed Nov. 6, 2009.

U.S. Appl. No. 12/617,998, filed Nov. 13, 2009.
U.S. Appl. No. 12/640,440, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,469, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,476, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,492, filed Dec. 17, 2009.
U.S. Appl. No. 12/641,823, filed Dec. 18, 2009.
U.S. Appl. No. 12/641,853, filed Dec. 18, 2009.
U.S. Appl. No. 12/641,837, filed Dec. 18, 2009.
U.S. Appl. No. 12/651,181, filed Dec. 31, 2009.
U.S. Appl. No. 12/696,598, filed Jan. 29, 2010.
U.S. Appl. No. 12/696,626, filed Jan. 29, 2010.
U.S. Appl. No. 12/752,701, filed Apr. 1, 2010.
International Search Report and Written Opinion for PCT/US2008/085771, Oct. 30, 2009 (14 pages).
Partial International Search Report for PCT/US2008/053973, Oct. 16, 2008 (2 pages).
International Search Report for PCT/US2008/053973, Dec. 22, 2008 (9 pages).
International Preliminary Report on Patentability for PCT/US2008/053973, Aug. 19, 2009 (12 pages).
U.S. Appl. No. 13/013,131, filed Jan. 25, 2011.
U.S. Appl. No. 13/013,147, filed Jan. 25, 2011.
U.S. Appl. No. 12/900,132, filed Oct. 7, 2010.
U.S. Appl. No. 12/939,441, filed Nov. 4, 2010.
U.S. Appl. No. 12/902,531, filed Oct. 12, 2010.
U.S. Appl. No. 12/902,550, filed Oct. 12, 2010.
Zadno et al., "Linear Superelasticity in Cold-Worked NI-TI," Engineering Aspects of Shape Memory Alloys, pp. 414-419 (1990).
U.S. Appl. No. 13/021,222, filed Feb. 4, 2011.

* cited by examiner


ELECTRICAL WAVEFORM GENERATOR
14
62
16
18
18
34
10
30
30
32
20
28
26
12

FIG. 1



FIG. 2



FIG. 3A



FIG. 3B



FIG. 4



FIG. 5



FIG. 6



FIG. 7



FIG. 8



FIG. 10



FIG. 9



FIG. 11


80
82
84
PATIENT
IMAGE INFORMATION - X-RAY, MRI, Z IMAGING..
89
88
14
WAVEFORM GENERATOR
IMAGE PROCESSING MODULE
86

FIG. 12


14
ELECTRICAL WAVEFORM GENERATOR
96
90
98
94
92
100

FIG. 13


NO PLUG
CONDUCTIVITY=0.2 S/m
CONDUCTIVITY=0.5 S/m
ELECTRIC FIELD STRENGTH (V/m x e5)
DISTANCE ALONG THE TISSUE AT THE END OF THE ELECTRODE (mm)
110
112
114
116
118
14
12
10
8
6
4
2
0.3
0
2
4
6
8
10
12
14
16
18
20

FIG. 14


NO PLUG
CONDUCTIVITY=0.2 S/m
CONDUCTIVITY=0.5 S/m
112
114
116
118
110
ELECTRIC FIELD STRENGTH (V/m x e5)
2
0.3
0
2
4
6
8
10
12
14
16
18
20
DISTANCE ALONG THE TISSUE AT THE END OF THE ELECTRODE (mm)

FIG. 15

ELECTROPORATION ABLATION APPARATUS, SYSTEM, AND METHOD

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 11/706,766, filed Feb. 15, 2007, now U.S. Pat. No. 7,655,004, which is related to U.S. patent application Ser. No. 11/706,591, entitles ELECTRICAL ABLATION APPARATUS, SYSTEM, AND METHOD, each of which is incorporated herein by reference in its entirety.

BACKGROUND

Electrical therapy techniques have been employed in medicine to treat pain and other and other conditions. Electrical ablation techniques have been employed in medicine for the removal of diseased tissue or abnormal growths from the body. Nevertheless, there is a need for improved medical instruments to electrically ablate or destroy diseased tissue or abnormal growths from the body, such as cancer tissue. There may be a need for such electrical therapy techniques to be performed endoscopically.

Electrical therapy probes comprising electrodes may be required to electrically treat diseased tissue. The electrodes may be introduced into the patient endoscopically to the tissue treatment region by passing the electrodes through the working channel of an endoscope.

SUMMARY

In one general aspect, the various embodiments are directed to an ablation device. In one embodiment, the ablation device, comprises an elongate member comprising first and second channels. First and second probes are disposed within the respective first and second channels, where the first and second probes each define a central axis. First and second electrodes are coupled to distal ends of the respective first and second probes. A distance between the first and second electrodes is adjustable by rotating at least one of the first and second probes about the central axis of the at least one of the first and second probes.

FIGURES

The novel features of the various embodiments of the invention are set forth with particularity in the appended claims. The various embodiments of the invention, however, both as to organization and methods of operation, together with further objects and advantages thereof, may best be understood by reference to the following description, taken in conjunction with the accompanying drawings as follows.

FIG. **1** illustrates one embodiment of an endoscopic ablation system.

FIG. **2** is an enlarged view of one embodiment of a therapeutic/diagnostic probe of one embodiment of the endoscopic ablation system shown in FIG. **1**.

FIG. **3**A is a side view of a distal end of one embodiment of a therapeutic/diagnostic probe comprising a biopsy probe and an electrical therapy electrode assembly.

FIG. **3**B is a sectional view of one embodiment of a therapeutic/diagnostic probe taken along section line **3**B-**3**B showing the geometric relationship between the electrodes and the diagnostic probes.

FIG. **4** is a sectional view of the lower end of an esophagus and the upper portion of a stomach of a human being.

FIG. **5** illustrates the use of one embodiment of an endoscopic ablation system to treat diseased tissue in the lower esophagus.

FIG. **6** illustrates the use of one embodiment of an endoscopic ablation system to treat diseased tissue in the lower esophagus.

FIG. **7** illustrates one embodiment of a necrotic zone defined by the geometry and placement of the electrical therapy electrodes.

FIG. **8** is a sectional view taken along the longitudinal axis of one embodiment of an endoscopic ablation system shown in FIG. **1**.

FIG. **9** is an end view taken along line **9-9** of one embodiment of a therapeutic/diagnostic probe of the endoscopic ablation system shown in FIG. **8**.

FIG. **10** is a sectional view taken along line **10-10** of a rotation tube of the endoscopic ablation system shown in FIG. **8**.

FIG. **11** shows one embodiment of a distal portion of an endoscopic ablation system shown in FIG. **1** partially inserted into the esophagus of a patient.

FIG. **12** is a diagram of one embodiment of a control loop for one embodiment of an irreversible electroporation therapy procedure to treat diseased tissue as described herein.

FIG. **13** illustrates one embodiment of an electrical scalpel for dissecting tissue.

FIG. **14** is a graphical representation (graph) of electric field strength (along the y-axis) as a function of distance from an electrical therapy electrode under various conductivity environments near diseased tissue.

FIG. **15** is a close up of the graph shown in FIG. **14**.

DESCRIPTION

The various embodiments described herein are directed to diagnostic and electrical therapy ablation devices. The diagnostic devices comprise biopsy probes. The electrical therapy ablation devices comprise probes and electrodes that can be positioned in a tissue treatment region of a patient endoscopically. An endoscopic electrode is inserted through a working channel of an endoscope. The placement and location of the electrodes can be important for effective and efficient therapy. Once positioned, the electrical therapy electrodes deliver electrical current to the treatment region. The electrical current is generated by a control unit or generator external to the patient and typically has particular waveform characteristics, such as frequency, amplitude, and pulse width. Depending on the diagnostic or therapeutic treatment rendered, the probes may comprise one electrode containing both a cathode and an anode or may contain a plurality of electrodes with at least one serving as a cathode and at least one serving as an anode.

Electrical therapy ablation may employ electroporation, or electropermeabilization, techniques where an externally applied electrical field significantly increases the electrical conductivity and permeability of a cell plasma membrane. Electroporation is the generation of a destabilizing electric potential across biological membranes. In electroporation, pores are formed when the voltage across the cell plasma membrane exceeds its dielectric strength. Electroporation destabilizing electric potentials are generally in the range of several hundred volts across a distance of several millimeters. Below certain magnitude thresholds, the electric potentials may be applied across a biological membrane as a way of introducing some substance into a cell, such as loading it with a molecular probe, a drug that can change the function of the cell, a piece of coding DNA, or increase the uptake of drugs in cells. If the strength of the applied electrical field and/or

duration of exposure to it are properly chosen, the pores formed by the electrical pulse reseal after a short period of time, during which extra-cellular compounds have a chance to enter into the cell. Thus, below a certain threshold, the process is reversible and the potential does not permanently damage the cell membrane. This process may be referred to as reversible electroporation (RE).

On the other hand, the excessive exposure of live cells to large electrical fields (or potentials) can cause apoptosis and/or necrosis—the processes that result in cell death. Accordingly, this may be referred to irreversible electroporation (IRE) because the cells die when exposed to excessive electrical potentials across the cell membranes. The various embodiments described herein are directed to electrical therapy ablation devices such as electroporation ablation devices. In one embodiment, the electroporation ablation device may be an IRE device to destroy cells by applying an electric potential to the cell membrane. The IRE potentials may be applied to cell membranes of diseased tissue in order to kill the diseased cells. The IRE may be applied in the form of direct current (DC) electrical waveforms having a characteristic frequency, amplitude, and pulse width.

Electroporation may be performed with devices called electroporators, appliances which create the electric current and send it through the cell. The electroporators may comprise two or more metallic (e.g., Ag, AgCl) electrodes connected to an energy source to generate an electric field having a suitable characteristic waveform output in terms of frequency, amplitude, and pulse width.

Endoscopy means looking inside and refers to looking inside the human body for medical reasons. Endoscopy may be performed using an instrument called an endoscope. Endoscopy is a minimally invasive diagnostic medical procedure used to evaluate the interior surfaces of an organ by inserting a small tube into the body, often, but not necessarily, through a natural body opening. Through the endoscope, the operator is able to see abnormal or diseased tissue such as lesions and other surface conditions. The endoscope may have a rigid or a flexible tube or member and in addition to providing an image for visual inspection and photography, the endoscope enables taking biopsies, retrieving foreign objects, and introducing medical instruments to a tissue treatment region. Endoscopy is the vehicle for minimally invasive surgery.

The embodiments of the electrical therapy ablation devices may be employed for treating diseased tissue, tissue masses, tissue tumors, and lesions (diseased tissue). More particularly, the electrical therapy ablation devices may be employed in minimally invasive therapeutic treatment of diseased tissue. The electrical therapy ablation devices may be employed to deliver energy to the diseased tissue to ablate or destroy tumors, masses, legions, and other abnormal tissue growths. In one embodiment, the electrical therapy ablation devices and techniques described herein may be employed in the treatment of cancer by quickly creating necrosis of live tissue and destroying cancerous tissue in-vivo. These minimally invasive therapeutic treatment of diseased tissue where medical instruments are introduced to a tissue treatment region within the body of a patient through a natural opening are known as Natural Orifice Translumenal Endoscopic Surgery (NOTES)™.

A biopsy is a medical procedure involving the removal of cells or tissues for examination. The tissue is often examined under a microscope and can also be analyzed chemically (for example, using polymerase chain reaction [PCR] techniques). When only a sample of tissue is removed, the procedure is called an incisional biopsy or core biopsy. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. When a sample of tissue or fluid is removed with a needle, the procedure is called a needle aspiration biopsy. A procedure called "optical biopsy" may be employed where optical coherence tomography may be adapted to allow high-speed visualization of tissue in a living animal with a catheter-endoscope 1 millimeter in diameter. Optical biopsy may be used to obtain cross-sectional images of internal tissues.

Biopsy specimens may be taken from part of a lesion when the cause of a disease is uncertain or its extent or exact character is in doubt. Vasculitis, for instance, is usually diagnosed on biopsy. Additionally, pathologic examination of a biopsy can determine whether a lesion is benign or malignant, and can help differentiate between different types of cancer.

FIG. **1** illustrates one embodiment of an endoscopic ablation system **10**. The endoscopic ablation system **10** may be employed to electrically treat diseased tissue such as tumors and lesions. The endoscopic ablation system **10** may be configured to be positioned within a natural opening of a patient such as the colon or the esophagus and can be passed through the opening to a tissue treatment region. The illustrated endoscopic ablation system **10** may be used to treat diseased tissue via the colon or the esophagus of the patient, for example. The tissue treatment region may be located in the esophagus, colon, liver, breast, brain, and lung, among others. The endoscopic ablation system **10** can be configured to treat a number of lesions and ostepathologies including but not limited to metastatic lesions, tumors, fractures, infected site, inflamed sites, and the like. Once positioned at the target tissue treatment region, the endoscopic ablation system **10** can be configured to treat and ablate diseased tissue in that region. In one embodiment, the endoscopic ablation system **10** may be employed as a diagnostic instrument to collect a tissue sample using a biopsy device introduced into the tissue treatment region via an endoscope (e.g., the endoscopic ablation system **10**). In one embodiment, the endoscopic ablation system **10** may be adapted to treat diseased tissue, such as cancers, of the gastrointestinal (GI) tract or esophagus that may be accessed orally. In another embodiment, the endoscopic ablation system **10** may be adapted to treat diseased tissue, such as cancers, of the liver or other organs that may be accessible transanally through the colon and/or the abdomen.

One embodiment of the endoscopic ablation system **10** may be mounted on a flexible endoscope **12** (also referred to as endoscope **12**), such as the GIF-100 model available from Olympus Corporation. The flexible endoscope **12** includes an endoscope handle **34** and a flexible shaft **32**. The endoscopic ablation system **10** generally comprises one or more therapeutic/diagnostic probe **20**, a plurality of conductors **18**, a handpiece **16** having a switch **62**, and an electrical waveform generator **14**. In one embodiment, the electrical waveform generator **14** may be a high voltage direct current (DC) irreversible electroporation (IRE) generator. The therapeutic/diagnostic probe **20** is located at a distal end of the flexible shaft **32** and the conductors **18** attach to the flexible shaft **32** using a plurality of clips **30**. The therapeutic/diagnostic probe **20** comprises an elongate member attached to an electrical energy delivery device comprising one or more electrical therapy electrodes **28**. In one embodiment, the therapeutic/diagnostic probe **20** extends through a bore in the flexible shaft **32** such as a working channel **36** (FIG. **2**). In one embodiment, the therapeutic/diagnostic probe **20** may comprise elongate diagnostic probes **26** attached or joined to the electrodes **28** that extend through the working channel **36**. In another embodiment, the flexible shaft **32** may comprise two working channels **36** and a first diagnostic probe **26** joined to a first electrode **28** that extends through the distal end of a first

working channels **36** and a second diagnostic probe **26** joined to a second electrode **28** that extends through the distal end of a second working channel **36**. In one embodiment, the diagnostic probe comprises one or more diagnostic probes **26** attached or joined in any suitable manner to the electrodes **28**. For example, the diagnostic probes **26** may be joined or attached to the electrodes **28** by welding, soldering, brazing or other well known techniques. Many different energy sources may be used for welding, soldering, or brazing such as, for example, a gas flame, an electric arc, a laser, an electron beam, friction, and ultrasound. Thus, in one embodiment, the therapeutic/diagnostic probe **20** may be employed in a diagnostic mode to take a biopsy sample of the diseased tissue using the diagnostic probes **26** and, in one embodiment the therapeutic/diagnostic probe **20** may be employed in a therapeutic mode by treating diseased tissue with electrical current delivered by the electrodes **28**. In other embodiments, the therapeutic/diagnostic probe **20** may be employed in a combination of therapeutic and diagnostic modes. The therapeutic/diagnostic probe **20** may be passed though the one or more working channels **36** located within the flexible shaft **32**. The therapeutic/diagnostic probe **20** is delivered to the tissue treatment region endoscopically and is located on top of the diseased tissue to be electrically treated. Once the therapeutic/diagnostic probe **20** is suitably located by the operator, manual operation of the switch **62** on the handpiece **16** electrically connects or disconnects the electrodes **28** to the electrical waveform generator **14**. Alternatively, the switch **62** may be mounted on, for example, a foot switch (not shown).

In one embodiment, the electrical waveform generator **14** may be a conventional, bipolar/monopolar electrosurgical generator (ICC200 Erbe Inc.) or an IRE generator such as one of many models commercially available, including Model Number ECM800, available from BTX Boston, Mass. The IRE generator generates electrical waveforms having predetermined frequency, amplitude, and pulse width. The application of these electrical waveforms to the cell membrane causes the cell to die. The IRE electrical waveforms are applied to the cell membranes of diseased tissue in order to kill the diseased cells and ablate the diseased tissue. IRE electrical waveforms suitable to destroy the cells of diseased tissues energy are generally in the form of direct current (DC) electrical pulses delivered at a frequency in the range of 1-20 Hz, amplitude in the range of 100-1000 VDC, and pulse width in the range of 0.01-100 ms. For example, an electrical waveform having amplitude of 500 VDC and pulse duration of 20 ms may be delivered at a pulse repetition rate or frequency of 10 HZ can destroy a reasonably large volume of diseased tissue. Unlike RF ablation systems which require high power and energy input into the tissue to heat and destroy the tissue, IRE requires very little energy input into the tissue, rather the destruction of the tissue is caused by high electric fields. It has been determined that in order to destroy living tissue, the waveforms have to generate an electric field of at least 30,000V/m in the tissue treatment region. In one embodiment, the IRE generator **14** may generate voltages from about 100-1000 VDC. The IRE generator **14** may generate voltage pulses from 0.01-100 ms. These pulses may be generated at a suitable pulse repetition rate. The electrical current depends on the voltage amplitude, pulse width, pulse repetition rate, and the volume of tissue being treated. In one embodiment, the IRE generator **14** generates 20 ms pulses of 500 VDC amplitude between the electrodes **28**. The embodiments, however, are not limited in this context.

When using the IRE generator **14** in monopolar mode with two or more electrical therapy electrodes **28**, a grounding pad is not needed on the patient. Because a generator will typically be constructed to operate upon sensing connection of ground pad to the patient when in monopolar mode, it can be useful to provide an impedance circuit to simulate the connection of a ground pad to the patient. Accordingly, when the electrical ablation system **10** is used in monopolar mode without a grounding pad, an impedance circuit can be assembled by one skilled in the art, and electrically connected in series with one of the electrical therapy electrodes **28** that would otherwise be used with a grounding pad attached to a patient during monopolar electrosurgery. Use of an impedance circuit allows use of the IRE generator **14** in monopolar mode without use of a grounding pad attached to the patient.

FIG. **2** is an enlarged view of one embodiment of the therapeutic/diagnostic probe **20** of one embodiment of the endoscopic ablation system **10** shown in FIG. **1**. The therapeutic/diagnostic probe **20** extends through the distal end of the flexible shaft **32**. In one embodiment, the therapeutic/diagnostic probe **20** protrudes from the distal end of an internal lumen extending between the proximal and distal ends of the flexible endoscope **12**. In one embodiment, the therapeutic/diagnostic probe **20** may comprise a biopsy device adapted and configured to remove sample tissue using an incisional, core, needle aspiration, or optical biopsy techniques. In one embodiment, the biopsy device comprises one or more diagnostic probes **26**. As previously discussed, the electrical therapy electrodes **28** may be joined or attached to the diagnostic probes **26** in any suitable manner.

As previously discussed, the electrical therapy electrodes **28** are connected to the diagnostic probes **26** in any known suitable manner and are located in a spaced-apart relationship so as to define a distance D between the electrodes. The distance D is adjustable and can be increased or decreased by rotating one or both of the diagnostic probes **26**. The therapeutic/diagnostic probe **20** are rotatable about a central axis **39**. Thus, the diagnostic probes **26** and the electrodes **28** are rotatable about the central axis **39**. The electrodes **28** may be rotated to increase or decrease the relative distance D between the electrode **28** either to focus the energy in a smaller tissue region or to enlarge the tissue treatment region. In this manner, the operator can surround the diseased tissue such as a cancerous lesion, a polyp, or a tumor. The electrodes **28** are energized with the electrical waveform generator **14** to treat the diseased tissue. The diagnostic probes **26** have a sharp tooth **33** at the distal end and are moveable from the distal end to the proximal end of the flexible shaft **32** capable of slicing a thin section of the tissue to obtain a biopsy sample (shown in more detail below). The diagnostic probes **26** may comprise a bore **35** (FIGS. **3**A, B) at the distal end extending from a proximal end to the distal end of the diagnostic probes **26**. Suction may be applied at the proximal end of the probes to remove a tissue sample before and/or after treatment through the bore **35** (FIGS. **3**A, B) formed through the diagnostic probes **26**.

The electrical therapy electrodes **28** may be positioned in any orientation relative to the diagnostic probes **26**. The electrodes **28** and the diagnostic probes **26** may have any suitable shape. In the illustrated embodiment, the electrodes **28** may have a generally cuboidal shape and the diagnostic probes **26** may have an elongate cylindrical shape with a sharp tooth **33** and a bore **35** formed therein at the distal end. The electrical conductors **18** are electrically insulated from each other and surrounding structure except for the electrical connections the electrodes **28**. The distal end of the flexible shaft **32** of the flexible endoscope **12** may comprise a light source **40**, a viewing port **38**, and one or more working channels **36**. The viewing port **38** transmits an image within its field of view to an optical device such as a charge coupled device (CCD)

camera within the flexible endoscope **12** so that an operator may view the image on a display monitor (not shown). In the embodiment shown in FIG. **2**, the distal end of flexible shaft **32** is proximal to the electrodes **28** and is within the viewing field of the flexible endoscope **12** to enable the operator to see the diseased tissue to be treated between the electrodes **28**.

FIG. **3**A is a side view of the distal end of one embodiment of the therapeutic/diagnostic probe **20** comprising a biopsy probe **26** and an electrical therapy electrode **28** assembly. FIG. **3**B is a sectional view of one embodiment of a therapeutic/diagnostic probe **20** taken along section line **3**B-**3**B showing the geometric relationship between the electrodes **28** and the diagnostic probes **26**. In the embodiment illustrated in FIGS. **3**A, B, the cuboidal electrodes **28**, each have a width "w," a length "l," and a thickness or height "h." The electrodes **28** have parallel, adjacent edges **8** separated by a distance "D." This geometry of the electrodes **28**, the distance D between them, and the electrical waveform may be used to calculate an ablation index, which has particular significance to the location, size, shape, and depth of ablation achievable, as will be described later. The diagnostic probes **26** may be juxtaposed with the electrodes **28**. In this embodiment, the two cylindrically elongate diagnostic probes **26** have a bore **35** for removing ablated tissue or taking biopsy samples of the tissue by way of suction. The length of the diagnostic probes **26** may extend through the entire length of the flexible endoscope **12**. The conductors **18** are attached to the electrodes **28** in any suitable manner including welding, soldering, or brazing and may employ many different energy sources such as, for example, a gas flame, heat source, an electric arc, a laser, an electron beam, friction, and ultrasound. The electrodes **28** are attached to the diagnostic probes **26** and may be rotated about the central axis **39** in the directions indicated by arrows **31***a* and **31***b*.

FIG. **4** is a sectional view of the lower end of an esophagus **42** and the upper portion of a stomach **54** of a human being. The esophagus **42** has a mucosal layer **46**, a muscular layer **44**, and a region of diseased tissue **48**. The boundary between the mucosal layer **46** of the esophagus **42** and a gastric mucosa **50** of the stomach **54** is a gastro-esophageal junction **52**, which is approximately the location for the lower esophageal sphincter (LES). The LES allows food to enter the stomach **54** while preventing the contents of the stomach **54** from refluxing into the lower esophagus **42** and damaging the mucosal layer **46**. The diseased tissue **48** can develop when chronic reflux is not treated. In one form, the diseased tissue **48** may be, for example, intestinal metaplasia, which is an early stage of Barrett's esophagus. As can be seen in FIG. **4**, the esophagus **42** is relatively flaccid and contains numerous folds and irregularities on the interior lining.

FIG. **5** illustrates the use of one embodiment of the endoscopic ablation system **10** to treat the diseased tissue **48** in the lower esophagus **42**. The operator positions the therapeutic/diagnostic probe **20** using endoscopic visualization so that the diseased tissue **48** to be treated is within the field of view of the flexible endoscope **12**. Once the operator positions the therapeutic/diagnostic probe **20** such that the electrical therapy electrodes **28** are located above the diseased tissue **48**, the operator may energize the electrodes **28** with the electrical waveform generator **14** to destroy the diseased tissue **48** in the tissue treatment region. For example, the electrodes **28** may be energized with an electrical waveform having amplitude of approximately 500 VDC and a pulse width of approximately 20 ms at a frequency of approximately 10 Hz. In this manner, the diseased tissue **48** in the tissue treatment region may be destroyed. This procedure may take very little time and may be repeated to destroy relatively larger portions of the diseased tissue **48**. Suction may be applied to remove the treated tissue sample through the bore **35** formed in the diagnostic probes **26**.

FIG. **6** illustrates the use of the endoscopic ablation system **10** to treat the diseased tissue **48** in the lower esophagus **42**. As shown in the illustrated embodiment, the electrical therapy electrodes **28** can be rotated about the central axis **39** in the direction indicated by arrows **31***a* and **31***b*. The treated tissue can be sucked into the bore **35** of the biopsy probe **26** by applying suction to thereto.

FIG. **7** illustrates one embodiment of a necrotic zone **70** defined by the geometry and placement of the electrical therapy electrodes **28**. The energy delivered by the waveform to the electrodes **28** in terms of frequency, amplitude, and pulse width should be suitable to destroy the tissue in the necrotic zone **70**. Based on the location and geometry of the electrodes **28**, and the energy delivered thereto, the necrotic zone **70** in the illustrated embodiment may be approximated generally as a volume of width "wnz," a thickness "tnz," and a length "lnz." Energizing the electrodes **28** destroys the diseased tissue **48** within the necrotic zone **70**. In one embodiment, electrodes **28** with a width "w=0.5 mm," a length "l=10 mm," and a thickness "h=0.5 mm" (as shown in FIGS. **3**A, B) and a waveform of approximately 500 VDC, a pulse width of 20 ms, and a frequency of 10 Hz, would define a necrotic zone **70** with dimensions of approximately wnz=6 mm wide, lnz=10 mm long, and hnz=2 mm deep. If a biopsy indicates that the treatment region includes dysplastic or malignant cells, or if the treatment region is larger than the necrotic zone **70**, the process may be repeated until all the diseased tissue **48** is destroyed in the treatment region and clean margins are recorded. In one embodiment, optical biopsy may be used as an alternative to the vacuum diagnostic probes **26** shown in the illustrated embodiments.

FIG. **8** is a sectional view taken along the longitudinal axis of one embodiment of an endoscopic ablation system **10** shown in FIG. **1**. The distal portion of the flexible shaft **32** is located inside a rotation tube **22** of the endoscopic ablation system **10**. The pair of electrical conductors **18** pass through a strain relief **66** of a rotation knob **58**. In the illustrated embodiment an external tube **64** may be located over the flexible shaft **32** such that the conductors **18** pass between the external tube **64** and the rotation tube **22**. Each of the conductors **18** connect electrically to the electrical therapy electrodes **28** in the therapeutic/diagnostic probe **20**. The rotation tube **22** rotatably joins the rotation knob **58**. The operator can rotatably orient the electrodes **28**, even after insertion into the esophagus, by remotely rotating the diagnostic probes **26** about the central axis **39** of each of the therapeutic/diagnostic probe **20**. The therapeutic/diagnostic probe **20** is within the field of view of the flexible endoscope **12**, thus enabling the operator to see on a display monitor the tissue that is located between the electrodes **28**. Optionally, in one embodiment, a valve element (not shown) may extend from the distal end of therapeutic/diagnostic probe **20** to prevent tissue or fluids from entering the therapeutic/diagnostic probe **20**.

FIG. **9** is an end view taken along line **9**-**9** of one embodiment of the therapeutic/diagnostic probe **20** of the endoscopic ablation system **10** shown in FIG. **8**. The electrical conductors **18** connect to the electrical therapy electrodes **28**. The rotation tube **22** retains the flexible shaft **32**. The inside diameter of the rotation tube **22** is larger than the outer diameter of the flexible endoscope **12** to allow rotation of the rotation tube **22** while holding the flexible endoscope **12** stationary, or vice versa. Each of the therapeutic/diagnostic probe **20** comprising the diagnostic probes **26** attached to the electrodes **28** extend outwardly from the distal end of the flexible shaft **32**

through each of the working channels **36**. In this embodiment, the operator may endoscopically view the tissue between the electrodes **28**. The flexible endoscope **12** includes the light source **40**, the viewing port **38**, and the one or more working channels **36**.

FIG. **10** is a sectional view taken along line **10-10** of the rotation tube **22** of the endoscopic ablation system **10** shown in FIG. **8**. The external tube **64** and the rotation tube **22** assemble and retain the electrical conductors **18** as already described. The light source **40**, the viewing port **38**, and the one or more working channels **36** of the flexible endoscope **12** are shown.

FIG. **11** shows one embodiment of the distal portion of the endoscopic ablation system **10** shown in FIG. **1** partially inserted into the esophagus **42** of a patient. A tapered end cover **84** dilates the esophagus **42** as the operator gently inserts the therapeutic/diagnostic probe **20** for positioning near the diseased tissue **48** to be ablated. A flexible coupling **88** flexes as shown, reducing the required insertion force and minimizing trauma (and post-procedural pain).

The operator may treat the diseased tissue **48** using the embodiment of the endoscopic ablation system **10** comprising the therapeutic/diagnostic probe **20** shown in FIGS. **1-3** and **5-11** as follows. The operator inserts the flexible shaft **32** of the endoscope **12** into the lower esophagus **42** trans-orally. A rigid support member at the distal end of the endoscope **12** holds the lower esophagus **42** open as the operator uses endoscopic visualization through the therapeutic/diagnostic probe **20** to position the electrical therapy electrodes **28** next to the diseased tissue **48** to be treated. The rigid support member opens and supports a portion of the flaccid, lower esophagus **42** and helps to bring the diseased tissue **48** to be treated into intimate contact with the electrodes **28** and within the field of view of the flexible endoscope **12**. While watching through the viewing port **38**, the operator actuates the switch **62**, electrically connecting the electrodes **28** to the electrical waveform generator **14** through the electrical conductors **18**. Electric current then passes through the portion of the diseased tissue **48** positioned between the electrodes **28** and within the field of view. When the operator observes that the tissue in the field of view has been ablated sufficiently, the operator deactuates the switch **62** to stop the ablation. The operator may reposition the electrodes **28** for subsequent tissue treatment, or may withdraw the therapeutic/diagnostic probe **20** (together with the flexible endoscope **12**).

FIG. **12** is a diagram of one embodiment of a control loop **80** for one embodiment of an IRE therapy procedure to treat diseased tissue as described herein. As previously discussed, the IRE therapy may be effective in quickly creating necrosis of live tissue and destroying diseased (e.g., cancerous) tissue in-vivo. Real time information feedback about the size in volume of a necrotic zone may be helpful during an IRE therapy procedure for focal treatment of diseased tissue **48**.

Prior to an IRE therapy procedure, a patient **82** will have an image of the diseased tissue **48** taken for clinical purposes in an effort to reveal, diagnose, or examine the diseased tissue **48** and to identify its location more precisely. The image information **84** will generally include geometric information about the volume of the diseased tissue **48**. The image information **84** is provided to an image processing module **86** to calculate the volume of the diseased tissue **48** and to display a virtual model of the diseased tissue **48** on a monitor. The image processing module **86** may comprise, for example, image processing software applications such as Comsol Multiphysics available by Comsol, Inc. to receive the image information **84**, extract the geometric information, and determine (e.g., calculate) the voltage required to treat the proper volume and outline of the necrotic zone required to treat the diseased tissue **48**. The image processing module **86** creates a virtual model of a treatment zone necessary to treat the diseased tissue **48**. The image processing module **86** then determines waveform parameters **88** of a suitable electrical waveform necessary to destroy the diseased tissue **48**. The waveform parameters **88** include the frequency, amplitude, and pulse width of the electrical waveform to be generated by the waveform generator **14**. The waveform generator **14** would then generate the suitable electrical waveform to destroy the diseased tissue **48** based on the calculated waveform parameters **88**.

The image processing module **86** also comprises image processing software applications such as Matlab available by MathWorks, Inc. to receive the image information **84** and the virtual model and display an image of the diseased tissue **48** overlaid with an image of the virtual model. The overlaid images enable the operator to determine whether the calculated electrical waveform parameters **88** are suitable for destroying the diseased tissue **48**, whether too strong or too weak. Thus, the IRE waveform parameters **88** may be adjusted such that the virtual model image substantially overlays the entire diseased tissue image. The calculated parameters **88** are provided to the waveform generator **14** and the diseased tissue may be treated with an electrical waveform **89** based on the calculated parameters **88** as discussed herein. After the diseased tissue **48** is treated with the electrical waveform **89**, a new image of the diseased tissue **48** can be generated to determine the extent or effectiveness of the treatment. The cycle may be repeated as necessary to ablate the diseased tissue **48** as much as possible.

FIG. **13** illustrates one embodiment of an electrical scalpel **90** for dissecting tissue **92**. In one embodiment, the electrical scalpel **90** may be driven by an IRE waveform previously described. The scalpel **90** comprises a blade **98** that is formed of metal such as hardened and tempered steel (and/or stainless in many applications). The blade **98** is connected to the electrical waveform generator **14** by multiple electrical conductors **96**. The electrical waveform generator **14** may generate an IRE waveform (e.g., 10 Hz frequency, 500 VDC amplitude, and 20 ms pulse). As the blade **98** dissects the tissue **92** along an incision **100**, the electrical waveform generator **14** may be activated or pulsed to create a tissue destruction zone **94** surrounding the blade **98**. Accordingly, as the blade **98** dissects the diseased tissue **92** it generates the tissue destruction zone **94** beyond the incision **100**. This may help to ensure the destruction of any diseased tissue cells left behind. The pulse repetition rate or frequency of the electrical waveform generated by the generator **14** may be selected to provide a continuous zone of tissue destruction **94** as the blade **98** moves through the diseased tissue **92**. In one embodiment, a feedback signal (e.g., audio, visual, or cut-off of electrical power to the blade **98**) may be provided to the operator to indicate that the scalpel **90** is moving too quickly.

FIG. **14** is a graphical representation **110** (graph) of electric field strength (along the y-axis) as a function of distance from an electrical therapy electrode **28** under various conductivity environments near the diseased tissue **48**. FIG. **15** is a close up of the graph **110** shown in FIG. **14**A. In electrical therapy of diseased tissue **48**, the volume of tissue that can be destroyed by an electrical waveform (e.g., the necrotic zone) may be defined by a minimum electric field strength applied to the tissue treatment region. The electric field strength in the tissue treatment region varies throughout the tissue as a function of the applied electrical waveform parameters frequency, amplitude, and pulse width as well as the conductivity of the tissue in the treatment region. When a single electrical therapy

electrode **28** is located in a first position in the tissue treatment region of interest and a return pad is placed at a distance relatively far from the first position, an electric field is generated around the electrode **28** when it is energized with a particular electrical waveform. The magnitude of the electric field, however, diminishes rapidly in the radial direction away from the electrode **28**. When two electrodes **28** are placed relatively close together, a larger pattern of tissue can be destroyed. Injecting a fluid having a higher conductivity than the tissue into the tissue treatment region extends the electric field of sufficient strength to destroy the tissue radially outwardly from the electrode **28**. Thus, the addition of a fluid having higher conductivity than the tissue to be treated creates a larger tissue destruction zone by extending the electric field radially outwardly from the electrodes **28**.

The graph **110** illustrates the electric field strength, along the y-axis, as a function of the radial distance from the electrical therapy electrode **28**. The y-axis is labeled in units of volts/meter ($V/m \times e^5$) and the x-axis is labeled in units of mm. The graph **110** illustrates a family of three functions with conductivity as a parameter. A first function **112** illustrates the electric field strength as a function of the radial distance from one of the electrodes **28** with no conductivity plug introduced into the tissue treatment region. A second function **114** illustrates the electric field strength as a function of the radial distance from one of the electrodes **28** with a conductivity plug of 0.2 S/m introduced in the tissue treatment region. A third function **116** illustrates the electric field strength as a function of the radial distance from one of the electrodes **28** with a conductivity plug of 0.5 S/m introduced in the tissue treatment region. As shown in the graph **110**, the peak electric field strength of each of the functions **112**, **114**, **116** decreases with increased conductivity in the tissue treatment region in proximity to the electrode **28**. However, the threshold **118** of each of the functions **112**, **114**, **116** where the electric field strength drops below the minimum threshold **118** of electric field strength required to destroy tissue becomes wider as the conductivity increases. In other words, increasing the conductivity of the tissue in the tissue treatment region extends the range of an effective electric field to destroy tissue or creates a larger necrotic zone. In one embodiment, the minimum electric field strength threshold **118** is approximately 30,000V/m.

The devices disclosed herein can be designed to be disposed of after a single use, or they can be designed to be used multiple times. In either case, however, the device can be reconditioned for reuse after at least one use. Reconditioning can include any combination of the steps of disassembly of the device, followed by cleaning or replacement of particular pieces, and subsequent reassembly. In particular, the device can be disassembled, and any number of the particular pieces or parts of the device can be selectively replaced or removed in any combination. Upon cleaning and/or replacement of particular parts, the device can be reassembled for subsequent use either at a reconditioning facility, or by a surgical team immediately prior to a surgical procedure. Those skilled in the art will appreciate that reconditioning of a device can utilize a variety of techniques for disassembly, cleaning/replacement, and reassembly. Use of such techniques, and the resulting reconditioned device, are all within the scope of the present application.

Preferably, the various embodiments of the invention described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed container, such as a plastic or TYVEK bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.

It is preferred that the device is sterilized. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam.

Although the various embodiments of the invention have been described herein in connection with certain disclosed embodiments, many modifications and variations to those embodiments may be implemented. For example, different types of end effectors may be employed. Also, where materials are disclosed for certain components, other materials may be used. The foregoing description and following claims are intended to cover all such modification and variations.

Any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.

What is claimed is:

1. An ablation device, comprising:

an elongate member comprising first and second channels;

first and second substantially straight probes disposed within the respective first and second channels, the first and second substantially straight probes each defining a central axis; and

first and second electrodes coupled to and juxtaposed with distal ends of the respective first and second substantially straight probes;

wherein a distance between the first and second electrodes is adjustable by rotating at least one of the first and second substantially straight probes about the respective central axis of the at least one of the first and second substantially straight probes;

wherein the first probe comprises a sharp distal end and an aperture in communication with a bore formed within the first probe to receive a tissue sample therethrough.

2. The ablation device of claim **1**, comprising:

at least one illuminator positioned to illuminate tissue; and

an image sensor positioned to image tissue therethrough.

3. The ablation device of claim **1**, wherein at least one of the first and second channels is a working channel.

4. The ablation device of claim **1**, wherein at least one of the first and second probes is a diagnostic probe.

5. The ablation device of claim **1**, wherein the elongate member is flexible.

6. An ablation system, comprising:

an elongate member comprising first and second channels;

first and second substantially straight probes disposed within the respective first and second channels, the first and second substantially straight probes each defining a central axis;

first and second electrodes coupled to and juxtaposed with distal ends of the respective first and second substantially straight probes; and

an electrical waveform generator electrically coupled to the first and second electrodes to generate an irreversible electroporation electrical (IRE) waveform sufficient to ablate tissue located proximate to the first and second electrodes;

wherein a distance between the first and second electrodes is adjustable by rotating at least one of the first and second substantially straight probes about the respective central axis of the at least one of the first and second substantially straight probes;

wherein the first probe comprises a sharp distal end and an aperture in communication with a bore formed within the first probe to receive a tissue sample therethrough.

7. The ablation system of claim **6**, comprising:

at least one illuminator positioned to illuminate tissue; and

an image sensor positioned to image tissue therethrough.

8. The ablation device of claim **6**, wherein at least one of the first and second channels is a working channel.

9. The ablation device of claim **6**, wherein at least one of the first and second probes is a diagnostic probe.

10. The ablation device of claim **6**, wherein the elongate member is flexible.

11. The ablation system of claim **6**, wherein the electrical waveform generator is adapted to receive IRE electrical waveform parameters from an image processing module; and wherein the IRE electrical waveform parameters are determined based on image information of a tissue treatment region in a patient.

12. The ablation system of claim **11**, wherein the IRE electrical waveform parameters are determined based on a volume and outline of a necrotic zone required to treat the tissue treatment region based on the image information.

13. The ablation system of claim **12**, wherein the volume and outline of the necrotic zone are determined from geometric information extracted from the image information.

14. The ablation system of claim **11**, wherein the IRE electrical waveform parameters comprise amplitude, frequency, and pulse width of an electrical waveform suitable to destroy the diseased tissue.

15. A method, comprising:

locating an elongate member comprising first and second channels within a body cavity proximate to a tissue treatment region, wherein a first and a second substantially straight probe are disposed within the respective first and second channels, the first and second substantially straight probes each defining a central axis, and wherein a first and a second electrode are coupled to and juxtaposed with distal ends of the respective first and second substantially straight probes;

adjusting a distance between the first and second electrodes by rotating at least one of the first and second substantially straight probes about the respective central axis of the at least one of the first and second substantially straight probes; and

receiving a tissue sample through a sharp distal end and an aperture in communication with a bore formed within either one of the first and second probes.

16. The method of claim **15**, comprising:

illuminating the tissue treatment region with at least one illuminator positioned to illuminate tissue; and

imaging the tissue treatment region with an image sensor positioned to image tissue therethrough.

17. The method of claim **15**, comprising:

applying an irreversible electroporation electrical (IRE) waveform sufficient to ablate tissue located proximate to the first and second electrodes with an electrical waveform generator electrically coupled to the first and second electrodes of the ablation device.

18. The method of claim **15**, comprising:

determining IRE electrical waveform parameters based on image information of the tissue treatment region; and

receiving by the electrical waveform generator IRE electrical waveform parameters from an image processing module.

19. The method of claim **18**, comprising determining the IRE electrical waveform parameters based on a volume and outline of a necrotic zone required to treat the tissue treatment region based on the image information.

20. The method of claim **19**, comprising determining the volume and outline of the necrotic zone from geometric information extracted from the image information.

21. The method of claim **15**, comprising applying an IRE electrical waveform suitable to destroy diseased tissue in the tissue treatment region, wherein the IRE electrical waveform parameters comprise amplitude, frequency, and pulse width.

22. An ablation device, comprising:

an elongate member comprising first and second channels;

first and second substantially straight probes disposed within the respective first and second channels, the first and second substantially straight probes each defining a central axis; and

first and second electrodes coupled to and juxtaposed with distal ends of the respective first and second substantially straight probes;

wherein a distance between the first and second electrodes is adjustable by rotating at least one of the first and second substantially straight probes about the respective central axis of the at least one of the first and second substantially straight probes;

wherein the second probe comprises a sharp distal end and an aperture in communication with a bore formed within the second probe to receive a tissue sample therethrough.

23. The ablation device of claim **22**, comprising:

at least one illuminator positioned to illuminate tissue; and

an image sensor positioned to image tissue therethrough.

24. The ablation device of claim **22**, wherein at least one of the first and second channels is a working channel.

25. The ablation device of claim **22**, wherein at least one of the first and second probes is a diagnostic probe.

26. The ablation device of claim **22**, wherein the elongate member is flexible.

27. An ablation system, comprising:

an elongate member comprising first and second channels;

first and second substantially straight probes disposed within the respective first and second channels, the first and second substantially straight probes each defining a central axis;

first and second electrodes coupled to and juxtaposed with distal ends of the respective first and second substantially straight probes; and

an electrical waveform generator electrically coupled to the first and second electrodes to generate an irreversible electroporation electrical (IRE) waveform sufficient to ablate tissue located proximate to the first and second electrodes;

wherein a distance between the first and second electrodes is adjustable by rotating at least one of the first and second substantially straight probes about the respective central axis of the at least one of the first and second substantially straight probes;

wherein the second probe comprises a sharp distal end and an aperture in communication with a bore formed within the second probe to receive a tissue sample therethrough.

28. The ablation system of claim **27**, comprising:

at least one illuminator positioned to illuminate tissue; and

an image sensor positioned to image tissue therethrough.

29. The ablation device of claim **27**, wherein at least one of the first and second channels is a working channel.

30. The ablation device of claim **27**, wherein at least one of the first and second probes is a diagnostic probe.

31. The ablation device of claim **27**, wherein the elongate member is flexible.

32. The ablation system of claim **27**, wherein the electrical waveform generator is adapted to receive IRE electrical waveform parameters from an image processing module; and wherein the IRE electrical waveform parameters are determined based on image information of a tissue treatment region in a patient.

33. The ablation system of claim **32**, wherein the IRE electrical waveform parameters are determined based on a volume and outline of a necrotic zone required to treat the tissue treatment region based on the image information.

34. The ablation system of claim **33**, wherein the volume and outline of the necrotic zone are determined from geometric information extracted from the image information.

35. The ablation system of claim **32**, wherein the IRE electrical waveform parameters comprise amplitude, frequency, and pulse width of an electrical waveform suitable to destroy the diseased tissue.

* * * * *

专利名称(译)	电穿孔消融装置，系统和方法		
公开(公告)号	US8029504	公开(公告)日	2011-10-04
申请号	US12/635298	申请日	2009-12-10
[标]申请(专利权)人(译)	伊西康内外科公司		
申请(专利权)人(译)	爱惜康内镜手术，INC.		
当前申请(专利权)人(译)	爱惜康内镜手术，INC.		
[标]发明人	LONG GARY L		
发明人	LONG, GARY L.		
IPC分类号	A61B18/04 A61B1/00		
CPC分类号	A61B18/1492 A61N1/327 A61B1/018 A61B1/04 A61B1/06 A61B18/1482 A61N1/306 A61B2018/00482 A61B2018/00577 A61B2018/00613		
其他公开文献	US20100087813A1		
外部链接	Espacenet USPTO		

摘要(译)

诸如内窥镜或腹腔镜器械的手术器械包括消融装置。消融装置包括细长构件，该细长构件包括第一和第二通道。第一和第二探针设置在相应的第一和第二通道内，其中第一和第二探针各自限定中心轴。第一和第二电极连接到相应的第一和第二探针的远端。通过围绕第一和第二探针中的至少一个的中心轴旋转第一和第二探针中的至少一个，可以调节第一和第二电极之间的距离。